Results

CDT Equity Inc.

11/17/2026 | Press release | Distributed by Public on 11/17/2026 08:16

Supplemental Prospectus (Form 424B3)

Filed Pursuant to Rule 424(b)(3)

File No. 333-298808

PROSPECTUS SUPPLEMENT NO. 8

(to Prospectus dated September 17, 2026)

CDT EQUITY INC.

33,649 Shares of Common Stock

This prospectus supplement supplements the prospectus dated September 17, 2026 (the "Prospectus"), which forms a part of our registration statement on Form S-1 (File No. 333-298808). This prospectus supplement is being filed to update and supplement the information in the Prospectus with the information contained in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission ("SEC") on November 16, 2026 (the "Form 10-Q"). Accordingly, we have attached the Form 10-Q to this prospectus supplement.

This prospectus relates to the offer and resale of shares (the "Shares") of our common stock, par value $0.0001 per share (the "Common Stock"), consisting of (i) up to 731 shares of Common Stock (the "Warrant Shares") underlying common stock purchase warrants (the "Warrants") issued to J.J. Astor & Co. (the "Lender"); (ii) 7,046 shares of Common Stock (the "Conversion Shares") issuable to the Lender pursuant to the senior secured convertible promissory note, dated June 11, 2026, as amended and restated on July 31, 2026 and August 3, 2026, in $2,536,650 aggregate principal amount and an additional $541,620 senior secured convertible promissory note issued to the Lender on August 31, 2026 (collectively, the "Notes"); (iii) 64 shares of Common Stock issued to EX-ANIMO Ltd. ("EX-ANIMO") on July 24, 2026 for certain consulting services; (iv) 50 shares of Common Stock issued to Maxim Partners LLC on July 30, 2026 as consideration for services provided to the Company; (v) 62 shares of Common Stock issued to Ian Burton on July 30, 2026 as consideration for services provided to the Company; (vi) 24,262 shares of Common Stock issued to shareholders of Sarborg Limited, a Cayman Islands company ("Sarborg"), pursuant to a Securities Purchase Agreement, dated July 30, 2026; (vii) 67 shares of Common Stock issued to NJS Foresight Bio-Advisory LLC ("NJS") on July 31, 2026 as consideration for services provided to the Company; (viii) 67 shares of Common Stock issued to Thesprogen, PC ("Thesprogen") on July 31, 2026 as consideration for services provided to the Company; and (ix) 1,300 shares of Common Stock issued to Sarborg pursuant to Amendment No. 1, dated August 31, 2026, to the Securities Purchase Agreement, dated February 19, 2026 (the "Amendment").

We are registering the Shares on behalf of the Selling Stockholders to be offered and sold by them from time to time. We are not selling any securities under this prospectus and will not receive any proceeds from the sale of our Common Stock by the Selling Stockholders in the offering described in this prospectus. The Selling Stockholders may sell any, all or none of the Shares offered by this prospectus. For more information, see "Use of Proceeds."

The Selling Stockholders, or their respective transferees, pledgees, donees or other successors-in-interest, may offer or sell the Shares from time to time in a number of different ways and at varying prices, including through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. See "Plan of Distribution" on page 108 of this prospectus for more information about how the Selling Stockholders may sell or dispose of the Shares being registered pursuant to this prospectus.

This prospectus describes the general manner in which the Shares may be offered and sold. When the Selling Stockholders sell Shares under this prospectus, we may, if necessary and required by law, provide a prospectus supplement that will contain specific information about the terms of that offering. Any prospectus supplement may also add to, update, modify or replace information contained in this prospectus. We urge you to read carefully this prospectus, any accompanying prospectus supplement and any documents we incorporate by reference into this prospectus and any accompanying prospectus supplement before you make your investment decision.

On November 2, 2026, the Company filed a certificate of amendment to the Company's Second Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of Delaware to effectuate a 1-for-20 reverse stock split (the "Reverse Stock Split") of the outstanding shares of the Company's Common Stock. Effective November 5, 2026 at 5:00 p.m. Eastern Time, every 20 shares of our Common Stock issued and outstanding immediately prior to the filing and effectiveness of our Certificate of Amendment were automatically combined and converted (without any further act) into one fully paid and non-assessable share of Common Stock. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders of record who would otherwise be entitled to receive a fractional share of Common Stock received a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing price per share of our Common Stock (as adjusted for the Reverse Stock Split) on The Nasdaq Capital Market on November 5, 2026.

All financial information, share numbers, option numbers, warrant numbers, other derivative security numbers and exercise prices appearing in this prospectus supplement have been adjusted to give effect to the Reverse Stock Split, except where otherwise stated.

Our Common Stock is traded on The Nasdaq Capital Market under the trading symbol "CDT." On November 16, 2026, the last reported sale price of our Common Stock on The Nasdaq Capital Market was $0.38.

We are an "emerging growth company," as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings.

Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section entitled "Risk Factors" beginning on page 8 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

You should rely only on the information contained in the Prospectus, this prospectus supplement or any other prospectus supplement or amendment thereto. We have not authorized anyone to provide you with different information.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 17, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-41245

CDT EQUITY INC.

(Exact name of registrant as specified in its charter)

Delaware 87-3272543

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

4581 Tamiami Trail North, Suite 200 Naples, Florida 34103
(Address of Principal Executive Offices) (Zip Code)
(646) 491-9132
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share CDT The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock CDTTW The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer ☐ Accelerated filer
☒ Non-accelerated filer ☒ Smaller reporting company
☒ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

As of November 16, 2026, there were 1,900,144 shares of common stock, $0.0001 par value (the "Common Stock") of the registrant issued and outstanding.

CDT EQUITY INC.

Form 10-Q

Table of Contents

Page
Part I-Financial Information.
Item 1. Financial Statements. 1
Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025. 1
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2026 and 2025. 2
Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2026 and 2025. 3
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025. 5
Notes to Unaudited Condensed Consolidated Financial Statements. 6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. 32
Item 3. Quantitative and Qualitative Disclosures About Market Risk. 44
Item 4. Controls and Procedures. 44
Part II-Other Information.
Item 1. Legal Proceedings. 45
Item 1A. Risk Factors. 45
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 45
Item 3. Defaults Upon Senior Securities. 45
Item 4. Mine Safety Disclosures. 45
Item 5. Other Information. 45
Item 6. Exhibits. 46
Part III-Signatures. 47
i

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this "Quarterly Report") for the quarterly period ended September 30, 2026 contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. This includes, without limitation, statements regarding the financial position and the plans and objectives of management for our future operations. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this Quarterly Report, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "strive," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described herein under "Item 1A. Risk Factors," those described in our Annual Report on Form 10-K for the year ended December 31, 2025, under "Item 1A. Risk Factors," filed with the U.S. Securities and Exchange Commission (the "SEC"). You are urged to consider these factors carefully when evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the filing date of this Quarterly Report. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the risk factors we describe in the reports we will file from time to time with the SEC after the date of this Quarterly Report.

This Quarterly Report may also contain market data related to our business and industry. These market data include projections that are based on a number of assumptions. If these assumptions turn out to be incorrect, actual results may differ from the projections based on these assumptions. As a result, our markets may not grow at the rates projected by these data, or at all. The failure of these markets to grow at these projected rates may harm our business, results of operations, financial condition, and the market price of our Common Stock.

ii

PART I-FINANCIAL INFORMATION

Item 1. Financial Statements.

CDT EQUITY INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

September 30, 2026 December 31, 2025
ASSETS
Current assets
Cash and cash equivalents $ 1,723 $ 1,509
Prepaid R&D services- related party (see Note 8 and Note 13) 533 881
Prepaid R&D services 298 166
Prepaid expenses and other current assets 1,834 1,823
Total current assets 4,388 4,379
Equity method investment 153,484 -
SAFE Note investment 100 -
Operating lease right-of-use assets, net 29 142
Equipment and clinical assets, net 102 269
Prepaid expenses and other long-term assets 623 860
Total assets $ 158,726 $ 5,650
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable $ 4,514 $ 1,913
Investment payable 6,108 -
Accrued expenses and other current liabilities 689 538
Accrued litigation liability 9,626 9,594
Operating lease liability, current portion 9 115
Convertible promissory notes payable at fair value 1,201 660
Total current liabilities 22,147 12,820
Derivative warrant liability 187 -
Total liabilities 22,334 12,820
Commitments and contingencies (see Note 15) - -
Stockholders' equity (deficit)
Common stock, par value $0.0001; 250,000,000 shares authorized at September 30, 2026 and December 31, 2025, 73,866 and 18 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively - -
Preferred stock, par value $0.0001; 1,000,000 shares authorized at September 30, 2026 and December 31, 2025; nil shares issued and outstanding at September 30, 2026 and December 31, 2025 - -
Additional paid-in capital 217,839 61,171
Accumulated deficit (81,612 ) (68,325 )
Accumulated other comprehensive income (loss) 165 (16 )
Total stockholders' equity (deficit) 136,392 (7,170 )
Total liabilities and stockholders' equity (deficit) $ 158,726 $ 5,650

The accompanying notes are an integral part of these condensed consolidated financial statements.

1

CDT EQUITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

(in thousands, except share and per share amounts)

Three Months ended

September 30,

Nine Months ended

September 30

2026 2025 2026 2025
Operating expenses:
Research and development expenses $ 563 $ 1,532 $ 1,643 $ 4,308
General and administrative expenses 3,334 5,501 8,912 11,293
Total operating expenses 3,897 7,033 10,555 15,601
Operating loss (3,897 ) (7,033 ) (10,555 ) (15,601 )
Other income (expense):
Other expense, net (257 ) (44 ) (2,083 ) (2,036 )
Loss on equity method investment (298 ) - (452 ) -
Interest income - 7 - 19
Interest expense (131 ) (48 ) (197 ) (281 )
Total other expense, net (686 ) (85 ) (2,732 ) (2,298 )
Net loss $ (4,583 ) $ (7,118 ) $ (13,287 ) $ (17,899 )
Basic and diluted net loss per share $ (288.89 ) $ (1,779,500 ) $ (2,310.55 ) $ (8,949,500 )
Basic and diluted weighted-average common shares outstanding 15,864 4 5,751 2
Comprehensive loss:
Foreign currency translation adjustment 7 (52 ) 181 (197 )
Total comprehensive loss $ (4,576 ) $ (7,170 ) $ (13,106 ) $ (18,096 )

The accompanying notes are an integral part of these condensed consolidated financial statements.

2

CDT EQUITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

For the Three and Nine Months Ended September 30, 2026 and 2025

(unaudited)

(in thousands, except share amounts)

Common stock Treasury Additional
paid-in
Accumulated Accumulated
other
comprehensive

Total

stockholders'
equity

Shares Amount Stock capital deficit income (deficit)
Balance at July 1, 2025 2 $ - $ (106 ) $ 43,248 $ (39,882 ) $ 269 $ 3,529
Issuance of common stock under the ATM Program 6 - - 6,008 - - 6,008
Issuance of common stock upon exercise of conversion option 1 - - 333 - - 333
Issuance of common stock upon vesting of restricted stock units - - - - - - -
Stock-based compensation 1 - - 1,578 - - 1,578
Share cancellation - - 106 (106 ) - - -
Foreign currency translation adjustment - - - - - (52 ) (52 )
Net loss - - - - (7,118 ) - (7,118 )
Balance at September 30, 2025 10 $ - $ - $ 51,061 $ (47,000 ) $ 217 $ 4,278
Common stock Treasury

Additional

paid-in

Accumulated

Accumulated

other

comprehensive

Total

stockholders'
equity

Shares Amount Stock capital deficit income (deficit)
Balance at January 1, 2025 1 $ - $ - $ 21,894 $ (29,101 ) $ 414 $ (6,793 )
Issuance of common stock for services - - - 2,952 - - 2,952
Issuance of common stock under the ATM Program 7 - - 18,063 - - 18,063
Issuance of common stock upon exercise of conversion option 1 - - 6,286 - - 6,286
Issuance of common stock upon vesting of restricted stock units - - - - - - -
Stock-based compensation 1 - 1,972 - - 1,972
Share repurchases - - (106 ) - - - (106 )
Share cancellation - - 106 (106 ) - - -
Foreign currency translation adjustment - - - - (197 ) (197 )
Net loss - - - (17,899 ) - (17,899 )
Balance at September 30, 2025 10 $ - - $ 51,061 $ (47,000 ) $ 217 $ 4,278
3
Common stock Additional
paid-in
Accumulated Accumulated
other
comprehensive

Total

stockholders'
equity

Shares Amount capital deficit income (deficit)
Balance at July 1, 2026 1,250 $ - $ 179,964 $ (77,029 ) $ 158 $ 103,093
Issuance of common stock for services 310 - 433 - - 433
Issuance of common stock under the ATM Program 46,748 - 5,214 - - 5,214
Stock-based compensation - - 199 - - 199
Exercise of warrants attributable to investment 24,258 - - - - -
Issuance of common stock for investment 1,300 - 1,092 - - 1,092
Issuance of warrants upon investment - - 30,937 - - 30,937
Foreign currency translation adjustment - - - - 7 7
Net loss - - - (4,583 ) - (4,583 )
Balance at September 30, 2026 73,866 $ - $ 217,839 $ (81,612 ) $ 165 $ 136,392
Common stock

Additional

paid-in

Accumulated

Accumulated

other

comprehensive

Total

stockholders'
equity

Shares Amount capital deficit income (deficit)
Balance at January 1, 2026 18 $ - $ 61,171 $ (68,325 ) $ (16 ) $ (7,170 )
Issuance of common stock for services 315 - 963 - - 963
Issuance of common stock under the ATM Program 46,801 - 5,569 - - 5,569
Issuance of common stock upon exercise of conversion option 255 - 2,418 - - 2,418
Stock-based compensation - - 597 - - 597
Shares issued for equity line of credit 7 - 92 - - 92
Issuance of common stock for investment 1,304 - 1,714 - - 1,714
Issuance of warrants upon investment - 145,315 - - 145,315
Exercise of warrants attributable to investment 25,137 - - - - -
Exercise of warrants attributable to the sale of previously
controlled subsidiary
29 - - - - -
Foreign currency translation adjustment - - - - 181 181
Net loss - - - (13,287 ) - (13,287 )
Balance at September 30, 2026 73,866 $ - $ 217,839 $ (81,612 ) $ 165 $ 136,392

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

CDT EQUITY INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

(in thousands)

Nine Months ended September 30,
2026 2025
Cash flows from operating activities:
Net loss $ (13,287 ) $ (17,899 )
Adjustments to reconcile net loss to net cash used in operating activities:
Loss (gain) on debt extinguishment, net 2,152 (281 )
Unrealized foreign exchange (gain) loss - (28 )
Loss on change in fair value of convertible notes payable 1,183 3,001
Gain on change in fair value of derivative warrant liability (465 ) (137 )
Loss on change in fair value of crypto holdings - 8
Loss on equity method investment 452 -
Gain on waiver of accrued interest - (371 )
Gain on waiver of consideration payable for investment in related party (640 )
Stock-based compensation expense 597 1,972
Non-cash interest expense 258 280
Non-cash lease expense 106 71
Depreciation expense 17 16
Amortization of financed directors and officers insurance 926 1,129
Issuance of common stock for services 963 -
Amortization expense 1,378 1,894
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (1,691 ) (155 )
Accounts payable 2,622 (840 )
Accrued expenses and other liabilities 219 517
Lease liability (105 ) (96 )
Net cash flows used in operating activities (5,315 ) (10,919 )
Cash flows from investing activities:
Purchases of equipment and clinical assets - (398 )
Purchase of digital assets - (1,000 )
Investment in related party (150 ) -
Purchases of short-term investments - (5 )
Net cash flows used in investing activities (150 ) (1,403 )
Cash flows from financing activities:
Net proceeds from the issuance of notes payable 3,860 -
Proceeds from issuance of common shares related to the ATM program 5,569 17,956
Repayment of notes payable - related parties (482 ) (425 )
Repayment of notes payable (3,268 ) (158 )
Repayment of convertible notes payable - related parties - (927 )
Repayment of convertible notes payable - (659 )
Purchases of treasury stock - (106 )
Net cash flows provided by financing activities 5,679 15,681
Net change in cash and cash equivalents before effect of exchange rate changes 214 3,359
Effect of exchange rate changes on cash and cash equivalents - (75 )
Net change in cash 214 3,284
Cash and cash equivalents at beginning of period 1,509 554
Cash and cash equivalents at end of period $ 1,723 $ 3,838
Supplemental cash flow information:
Cash paid for interest $ 11 $ -
Cash paid for taxes $ - $ -
Non-cash investing and financing activities
Issuance of common stock upon exercise of conversion option $ 2,418 $ 6,286
Issuance of common stock for services $ 963 2,952
Issuance of common stock for investment in related party $ 1,714 $ -
Deferred cash payable for investment in related party $ 6,008 $ -
Deferred cash payable for investment in related party SAFE Note $ 100 $ -
Issuance of pre-funded warrants for investment in related party $ 145,315 $ -
Issuance of warrants upon the issuance of convertible note $ 652 $ -
Cancellation of shares $ - $ 106

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

CDT EQUITY INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Nature of the Business

CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation ("CDT", "CDT Equity" or the "Company"), is a data-driven pharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.

The Company's strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, the Company improves drug properties and extends patent life by up to 20 years. In partnership with Sarborg Limited, the Company also applies AI-powered disease mapping to rapidly identify new therapeutic applications for existing compounds.

The Company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, and animal health. Ongoing in vitro and in vivo studies, guided by AI insights, are designed to support licensing and commercialization partnerships. The Company will seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials, by entering into agreements with third-parties to pursue further development, FDA approval, commercialization and marketing of the Company's assets.

Operating with a lean, asset-agnostic model, CDT Equity prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies.

Effective August 5, 2025, the Company changed its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Our change to CDT Equity Inc. reflects the evolution of our strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.

On September 25, 2023, the Company's Common Stock commenced trading on the Nasdaq Capital Market under the symbol "CDT".

Reverse Stock Splits

The Company completed seven reverse stock splits: a 1-for-100 split effective January 24, 2025 (the "January 2025 Reverse Stock Split"), a 1-for-15 split effective May 19, 2025 (the "May 2025 Reverse Stock Split"), a 1-for-8 split effective October 10, 2025 (the "October 2025 Reverse Stock Split"), a 1-for-25 reverse stock split effective March 26, 2026 (the "March 2026 Reverse Stock Split"), a 1-for-10 reverse stock split effective July 20, 2026 (the "July 2026 Reverse Stock Split"), a 1-for-25 reverse stock split effective September 28, 2026 (the "September 2026 Reverse Stock Split") and a 1-for-20 reverse stock split effective November 5, 2026 (the "November 2026 Reverse Stock Split"). The January 2025 Reverse Stock Split, May 2025 Reverse Stock Split, October 2025 Reverse Stock Split, March 2026 Reverse Stock Split, July 2026 Reverse Stock Split, September 2026 Reverse Stock Split and November 2026 Reverse Stock Split are reflected collectively (the "Reverse Stock Splits"). Each split reduced the number of issued and outstanding shares without affecting the number of authorized shares or the par value of the Common Stock. No fractional shares were issued; instead, stockholders received cash in lieu of fractional shares based on the respective post-split closing share prices. All share and per-share information has been retroactively adjusted to reflect the Reverse Stock Splits for all periods presented.

All historical share and per-share amounts reflected throughout the accompanying unaudited consolidated financial statements and related disclosures as of and for the nine months ended September 30, 2026 and 2025 have been retroactively adjusted to reflect the January 2025 Reverse Stock Split, May 2025 Reverse Stock Split, October 2025 Reverse Stock Split, March 2026 Reverse Stock Split, July 2026 Reverse Stock Split, September 2026 Reverse Stock Split, and November 2026 Reverse Stock Split as if the Reverse Stock Splits occurred as of the earliest period presented.

6

2. Liquidity and Going Concern

In accordance with ASC 205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. Since its inception, the Company has generated significant losses and as of September 30, 2026, the Company had an accumulated deficit of $81.6 million. As of September 30, 2026, the Company had cash and cash equivalents of $1.7 million. For the nine months ended September 30, 2026, the Company had a net loss of $13.3 million, and cash used in operating activities of $5.3 million.

Management has determined that it does not currently have sufficient cash and other sources of liquidity to fund its current business plan. These factors raise substantial doubt regarding the Company's ability to continue as a going concern for at least the next 12 months from the financial statement filing date.

The Company's expectation is to generate operating losses and negative operating cash flows in the future and will need additional funding to support its current business plan in addition to the funds available from the at the market offering program (the "Sales Agreement"). The Company currently has approximately $68 million of available funds remaining from the Sales Agreement as of November 13, 2026, when accounting for the $2.7 million due pursuant to convertible notes issued to J.J. Astor via the convertible note agreement entered into during the nine months ended September 30, 2026 (the "J.J. Astor Notes"). The available funds from the Sales Agreement is subject to further reduction in the event of default. However, there is no assurance that such funding will be available when needed. If additional funding is not available when required, the Company would need to delay or curtail its operations and its research and development activities until such funding is received, all of which could have a material adverse effect on the Company and its financial condition. See Note 7 for further discussion of the J.J. Astor Notes.

These unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

3. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") as set forth by the Financial Accounting Standards Board ("FASB") and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC"). References to U.S. GAAP issued by the FASB in these notes to the accompanying unaudited condensed consolidated financial statements are to the FASB Accounting Standards Codifications ("ASC") and Accounting Standards Updates ("ASUs").

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with U.S. GAAP for interim financial information, and with the rules and regulations of the SEC set forth in Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of the results for the full fiscal year. These unaudited condensed consolidated financial statements should be read along with our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on April 15, 2026. The consolidated balance sheet as of December 31, 2025 was derived from the audited consolidated financial statements as of and for the year then ended.

7

Formation of CDT Equity SEZC

On September 15, 2026, the Company formed CDT Equity SEZC, a wholly-owned subsidiary organized as an exempted company and registered as a Special Economic Zone Company under the Companies Act of the Cayman Islands. CDT Equity SEZC had no operations prior to formation, and its financial position and results of operations are included in the Company's unaudited condensed consolidated financial statements beginning on the date of formation. The formation of CDT Equity SEZC did not have a material effect on the Company's unaudited condensed consolidated financial statements.

Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CDT Equity Limited, formerly Conduit UK Management Ltd. (United Kingdom), Taamja Limited, formerly Conduit Pharmaceuticals, Ltd. (Cayman Islands) and CDT Equity SEZC (Cayman Islands). As used herein, references to the "Company" or "CDT" include references to CDT Equity Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Other Risks and Uncertainties

The Company is subject to risks common to companies in the development stage and pharmaceutical industry including, but not limited to, uncertainties related to pre-clinical and clinical outcomes competitor products, regulatory approvals, dependence on key products, dependence on key suppliers and protection of intellectual property rights (see Note 15 for details on a claim against our AZD 1656 co-crystal patent). Clinical assets currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts may require significant amounts of additional capital, adequate personnel, infrastructure, and extensive compliance and reporting capabilities. Even if the Company's efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from royalties or product sales.

The Company licenses clinical assets from AstraZeneca (see Note 8 for further detail). A breach or other termination of such agreements could have a material adverse effect on the Company's business, financial condition, operating results, and prospects.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Estimates are based on several factors including the facts and circumstances available at the time the estimates are made, historical experience, risk of loss, general economic conditions and trends, and the assessment of the probable future outcome. Actual results could differ materially from such estimates. Estimates and assumptions are reviewed periodically by management and changes in estimates are made as management becomes aware of changes in circumstances surrounding the estimates. The effects of changes are reflected in the financial statements in the period that they are determined. Our significant accounting policies that involve significant judgment and estimates include accounting for the fair value of convertible notes payable, stock based compensation, contingencies, equity method investment and going concern.

Fair Value Measurements

ASC Topic 820, Fair Value Measurements and Disclosures, defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Fair value is to be determined based on the exchange price that would be received for an asset or paid in order to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. In determining fair value, the Company used various valuation approaches. A fair value hierarchy has been established for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.

8

Unobservable inputs reflect the Company's assumption about the inputs that market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels, based on the inputs, as follows:

● Level 1-Valuations based on quoted prices for identical instruments in active markets. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these instruments does not entail a significant degree of judgment.
● Level 2-Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for either similar instruments in active markets, identical or similar instruments in markets that are not active, or model-derived valuations whose inputs or significant value drivers are observable or can be corroborated by observable market data.
● Level 3-Valuations based on inputs that are unobservable. These valuations require significant judgment.

The Company's Level 1 assets consist of cash and cash equivalents in the accompanying balance sheets, the value of accrued expenses and other current liabilities approximate fair value due to the short-term nature of these assets and liabilities.

As of September 30, 2026 the Company had four financial liabilities: one convertible note carried at fair value for which the fair value is based on Level 3 inputs and three warrant liabilities, for which the fair value is determined based on Level 2 inputs. As of December 31, 2025, the Company had two financial liabilities: one convertible note carried at fair value for which the fair value is determined based on Level 3 inputs, and a warrant liability, which was immaterial, for which the fair value is determined based on Level 2 and Level 3 inputs. The Level 2 inputs are valued based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar instruments in active markets. The Level 3 inputs are based on unobservable inputs and require significant judgment.

Fair Value Option

The Company has elected the fair value measurement option for each convertible debt note with embedded derivatives that would otherwise require bifurcation and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC 825, Financial Instruments. As a result, the March 2026 note ("Ascent Note") with Ascent Partners LLC ("Ascent"), the June 2026 Note, August 2026 Note and September 2026 Note ("J.J. Astor Notes") with J.J. Astor & Co. and the A.G.P. Convertible Note was recorded at fair value upon issuance. The notes are subsequently remeasured at fair value each reporting date until settled or converted. The Company reports interest expense, including accrued interest, related to the convertible debt under the fair value option, separately from within the change in fair value of the convertible debt in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss. Any changes in fair value caused by instrument-specific credit risk are presented separately in other comprehensive income. During the period ended September 30, 2026, the Company did not record any changes in fair value related to instrument-specific credit risk, considering the default identified in the lender schedule and the changes in the valuation assumptions.

Investments

In accordance with ASC 323, Investments - Equity Method and Joint Ventures ("ASC 323"), the Company accounts for investments in entities over which it has the ability to exercise significant influence, but does not hold a controlling financial interest, using the equity method of accounting. Significant influence is generally presumed to exist when the Company owns between 20% and 50% of the outstanding voting stock of the investee. Investments in which the Company does not have the ability to exercise significant influence are accounted for in accordance with ASC 321, Investments - Equity Securities ("ASC 321").

9

Investments are initially recorded at cost and subsequently adjusted to recognize the Company's share of the investee's net income or loss, with distributions recorded as reductions to the investment's carrying amount. The Company records its share of the results of these investees in the unaudited condensed consolidated statements of operations and comprehensive loss.

The Company evaluates its investments for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Any impairment is recognized in earnings for the amount by which the carrying value exceeds fair value and is determined to be other-than-temporary. There was no impairment of Sarborg identified or recorded during the nine months ended September 30, 2026.

ELOC

On January 16, 2026, the Company entered into a directed stock purchase agreement (the "Purchase Agreement") with an institutional investor relating to an equity line of credit facility (the "ELOC"). Pursuant to the ELOC, the Company will have the right from time to time at its option to sell to the purchaser up to $25 million of the Company's Common Stock, par value $0.0001 per share.

The Purchase Agreement is subject to certain customary conditions and limitations, including that (i) the Purchaser shall not be obligated to purchase or acquire any shares of Common Stock that would result in its beneficial ownership exceeding 9.99% of the Company's then-outstanding voting power and (ii) the Purchaser shall not be obligated to purchase shares of Common Stock if the volume weighted average price for the Common Stock on an advance notice date is less than a floor price of $15. On each six-month anniversary, the floor price will adjust to the lower of the Nasdaq Official Closing Price for the day prior to the relevant adjustment date, and the average of the Nasdaq Official Closing Price for the five-day period prior to the relevant adjustment date.

On March 3, 2026, the Company and the institutional investor entered into an amendment to the ELOC. The amendment updated the definition of the regular price floor from the minimum price as of the date of this agreement to $0.60 with no adjustment for reverse splits where applicable within the ELOC. No consideration was payable in connection with the amendment.

During April 2026, the Company sold 150 shares of the Company's Common Stock for proceeds of $0.1 million pursuant to the ELOC.

On May 15, 2026, the Company entered into the second amendment (the "Amendment No. 2") to the Purchase Agreement, dated January 16, 2026. Pursuant to Amendment No. 2, the parties mutually agreed to set the gross purchase price to be paid without the consent of the Purchaser at any closing of a regular purchase at $0.5 million. Amendment No. 2 also extends the Adjustment Period, as defined in the Purchase Agreement, to such time as the Purchaser has entered into committed and binding trades to sell all of the shares it purchased under the Purchase Agreement.

Foreign Currency Translation

The Company translates the assets and liabilities of foreign subsidiaries from their respective functional currency, the British pound, to United States dollars at the appropriate spot rates as of the balance sheet date. Income and expenses of operations are translated to United States dollars using weighted average exchange rates during the year. The foreign subsidiaries use the local currency as their functional currency. The effects of foreign currency translation adjustments are included as a component of accumulated other comprehensive income in the accompanying unaudited condensed consolidated statements of changes in stockholders' equity (deficit). Non-monetary items in the subsidiaries' functional currency are re-measured into the reporting currency at the historical exchange rate (i.e., the rate of exchange at the date of the transaction).

10

Recently Adopted Accounting Standards

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This ASU introduces a practical expedient for estimating expected credit losses on current accounts receivable and current contract assets arising from transactions accounted for under ASC 606, Revenue from Contracts with Customers. Under the expedient, entities may assume that the current conditions applied in determining credit loss allowances remain unchanged for the remaining life of those assets. This ASU is required to be adopted on a prospective basis. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, including interim periods within those years, with early adoption permitted. The Company adopted this standard, effective January 1, 2026. The adoption of ASU 2025-05 did not have a material impact on the Company's unaudited condensed consolidated financial statements.

Recently Issued Accounting Standards Not Yet Adopted

In December 2025, the FASB issued Accounting Standards Update No. 2025-11, Interim Reporting (Topic 270) Narrow-Scope Improvements ("ASU 2025-11"), to improve the navigability and clarity of interim reporting guidance in the FASB Accounting Standards Codification and clarify when Topic 270 applies. The amendments add a comprehensive list of interim disclosure requirements currently required by GAAP and a new disclosure principle requiring an entity to disclose events since the end of the most recent fiscal year that have a material impact on the entity's interim financial statements. ASU 2025-11 is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, for public business entities and after December 15, 2028 for entities other than public business entities. Early adoption is permitted. The Company is currently evaluating the potential impact of adopting ASU 2025-11 on our interim reporting practices and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statements of operations and comprehensive income (loss). The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the consolidated financial statements. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its consolidated financial statements and disclosures.

4. Investments

On February 19, 2026, the Company acquired a 20.0% equity interest in Sarborg, a Cayman Islands-based related party, for total consideration of $123 million. Total consideration consisted of 4 shares of the Company's Common Stock, pre-funded warrants to purchase up to 879 shares of the Company's Common Stock and $8 million of cash, payable upon the Company raising no less than $20 million through the use of an at-the-market facility program (the "Sales Agreement"). The Company expects to raise the $20 million and pay the investors of Sarborg the remaining cash consideration due within the next 12 months, subject to equity market conditions and the trading of the Company's Common Stock.

The pre-funded warrants portion of the consideration transferred had an exercise price of $12.50 per share, subject to adjustment as set forth therein and were not exercisable until such time as the Company obtained the requisite approval from its stockholders in accordance with applicable Nasdaq rules and requirements. On March 19, 2026, 879 pre-funded warrants were exercised through a cashless exercise into 879 shares of the Company's Common Stock. See Note 16 for further discussion of the pre-funded warrants issued to the investors of Sarborg.

On July 30, 2026, the Company entered into a Securities Purchase Agreement with shareholders of Sarborg. The investors of Sarborg agreed to sell to the Company, and the Company agreed to acquire from the shareholders of Sarborg, an aggregate of 270 shares of Sarborg, representing approximately 4.76% of the outstanding shares of Sarborg. As consideration for the purchase, the Company has agreed to issue to the shareholders of Sarborg, in the aggregate: pre-funded warrants to purchase up to 24,263 shares of the Company's Common Stock.

11

On August 28, 2026, following the receipt of stockholder approval, all of the pre-funded warrants were exercised on a cashless basis, and the Company issued an aggregate of 24,258 shares of the company's common stock.

On August 31, 2026, the Company entered into an amendment to the Securities Purchase Agreement, dated February 19, 2026. Pursuant to the amendment: (i) $1.75 million (or such other amount as may be mutually agreed) of the $8.0 million in cash consideration due can be satisfied through the issuance of shares of the Company's Common Stock to Sarborg, subject to a 4.99% beneficial ownership limitation; (ii) the Company agreed to pay certain audit costs incurred in connection with Sarborg's fiscal year 2024, fiscal year 2025, and pro-forma 2026 review, which amount shall be credited against the cash consideration owed to Sarborg; and (iii) the remaining cash consideration shall be paid from proceeds of the Company's at-the-market program, with the Company agreeing to make minimum payments of $150,000 per month and with any remaining outstanding balance due no later than May 31, 2027. On August 31, 2026, the Company issued 1,300 shares of Common Stock to Sarborg based on the price per share on August 28, 2026, to partially satisfy the $1.75 million payable in shares of the Company's Common Stock. During the three and nine months ended September 30, 2026, the Company paid $0.1 million of Sarborg's audit costs which was offset against the investment payable balance.

To date the Company owns 22.74% of the outstanding shares of Sarborg. The Company determined that it does have the ability to exercise significant influence over Sarborg through its ownership interest and participation in certain strategic and operating decisions and, accordingly, accounts for this investment under the equity method of accounting in accordance with ASC 323. The Company accounts for the investment at its carrying value less any impairment.

For the three and nine months ended September 30, 2026, the Company recognized a loss of $0.3 million and $0.5 million, respectively, representing its proportionate share of Sarborg's results of operations during the three and nine months ended September 30, 2026. As of September 30, 2026, the carrying value of the Company's investment in Sarborg was approximately $153.5 million.

The Company evaluated the equity method investment for impairment as of September 30, 2026, and determined that the decline in the Company's share price triggered that an impairment indicator was present. Based on the impairment indicator present, the Company evaluated Sarborg for impairment and determined there were no factors present at Sarborg that would indicate an impairment existed as of September 30, 2026. Furthermore, during June 2026, Sarborg sold shares to a third-party investor at a per share value in excess of the Company's cost basis in the shares of Sarborg. The Company will continue to periodically assess the equity method investment for impairment and record an impairment if deemed necessary in accordance with ASC 323.

Management determined that the accounting treatment for the Sarborg transaction required the filing of Sarborg's historical financial statements pursuant to applicable SEC reporting requirements. On August 21, 2026, The Company filed such historical financial statements in Amended Current Reports on Form 8-K/A to the Company's Current Report on Form 8-K filed on February 24, 2026, and Current Report on Form 8-K filed on July 31, 2026.

The investment in Sarborg has been accounted for using the equity method as follows:

September 30, 2026
Balance as of July 1, 2026 $ 122,846
Investment in Sarborg 30,936
Loss on equity investment in Sarborg (298 )
Impairment on equity investment in Sarborg -
Balance as of September 30, 2026 $ 153,484
September 30, 2026
Balance as of December 31, 2025 $ -
Investment in Sarborg 153,936
Loss on equity investment in Sarborg (452 )
Impairment on equity investment in Sarborg -
Balance as of September 30, 2026 $ 153,484
12

The following table presents the summarized financial information for Sarborg:

September 30, 2026
Current assets $ 206
Non-current assets $ 65,030
Total assets $ 65,236
Current liabilities $ 563
Non-current liabilities -
Total liabilities $ 563
Net assets $ 64,673
Company share of net assets $ 14,707
Revenue $ 768
Net loss $ (2,081 )
Company share of net loss $ (452 )

5. Fair Value

The following table presents, as of September 30, 2026, the Company's assets and liabilities subject to measurement at fair value on a recurring basis (in thousands):

Fair Value Measurements as of September 30, 2026
Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 1,474 $ - $ - $

1,474

Total Assets $ 1,474 $ - $ - $ 1,474
Liabilities:
Convertible notes payable, at fair value $ - $ - $ 1,201 $ 1,201
Derivative warrant liability $ - $ 187 $ - $ 187
Total Liabilities $ - $ 187 $ 1,201 $ 1,388

The following table presents as of December 31, 2025 the Company's assets and liabilities subject to measurement at fair value on a recurring basis (in thousands):

Fair Value Measurements as of December 31, 2025
Level 1 Level 2 Level 3 Total
Assets:
Cash equivalents $ 739 $ - $ - $ 739
Total Assets $ 739 $ - $ - $ 739
Liabilities:
Convertible notes payable, at fair value $ - $ - $ 660 $ 660
Total Liabilities $ - $ - $ 660 $ 660
13

The following table presents additional information about the Convertible Notes Payable subject to measurement at fair value on a recurring basis, for which the Company used significant unobservable inputs (Level 3) (in thousands):

Convertible

Notes Payable

Balance as of December 31, 2025 $ 660
Fair value at issuance 3,194
Conversion of convertible notes (681 )
Interest expense 258
Cash repayment (3,454 )
Change in fair value 1,224
Balance as of September 30, 2026 $ 1,201

During the nine months ended September 30, 2026, there were no transfers between Level 1 and Level 2, nor into or out of Level 3.

Convertible Notes Payable

As discussed in Note 3 and Note 7, During November 2024, the Company issued to Alliance Global Partners ("A.G.P.") a convertible promissory note (the "A.G.P. Convertible Note") in the principal amount of $5.7 million to evidence the A.G.P.'s currently owed deferred commission payable. The A.G.P. Convertible Note was settled in full as of September 30, 2026.

During March 2026, the Company issued to Ascent a convertible promissory note (the "Ascent Note") in the principal amount of $0.6 million. Subsequently, in June 2026 the Company repaid the outstanding indebtedness of the Ascent Note of $0.4 million.

During June 2026, the Company issued the J.J. Astor Note in the principal amount of $2.0 million, and received net proceeds of $1.5 million, funded in two tranches during June 2026. During July 2026 and August 2026, the Company amended the June 2026 Note to delay weekly payments and issued $0.8 million in additional principal to J.J. Astor and received additional net proceeds of $0.2 million.

During August 2026 the Company issued the Second J.J. Astor Note in the principal amount of $0.5 million and received net proceeds of $0.4 million. On September 4, 2026, the August 2026 Note was repaid in full and is no longer outstanding.

During September 2026 the Company issued the Third J.J. Astor Note in the principal amount of $2.1 million and received net proceeds of $1.5 million.

The Company elected to account for the Ascent Note, the A.G.P. Convertible Note, and the JJ Astor Convertible Notes (collectively the "Convertible Notes Payable") at fair value. The fair value of the Convertible Notes Payable is estimated each period using a discounted cash flow model in conjunction with a Bond plus Call model. Significant estimates in the binomial lattice model include the Company's stock price, volatility, risk-free rate, corporate bond yield, credit spread, probability of default, and recovery upon default.

The following table outlines the range of significant unobservable inputs used in calculating the fair value of the A.G.P. Convertible Note as of May 29, 2026, when the note was paid off in full, and December 31, 2025:

May 29, 2026 December 31, 2025
Stock Price $ 10.40 $ 32
Term (years) 0.15 0.40
Corporate bond yield 16.3 % 5.5 %
Credit Spread 26.2 % 26.2 %
Probability of default 70 % 70 %
Recovery upon default 0 % 0 %
Volatility 194 % 135 %
14

The August 2026 Note was repaid in full on September 4, 2026, and the September 2026 Note was also repaid in full on September 17, 2026 and both are no longer outstanding. Due to the proximity between the inception and repayment of the August 2026 Note and September 2026 Note, the Company believes the fair value of these notes at inception approximates the fair value at payoff. As such, the Company did not obtain an additional valuation as of the payoff date. The only outstanding J.J. Astor Note as of September 30, 2026 is the June 2026 Note. The following table outlines the range of significant unobservable inputs used in calculating the fair value of the J.J. Astor Notes.

As of September 30, 2026 As of August 31, 2026 As of September 14, 2026
June 2026 Note August 2026 Note September 2026 Note
Stock Price $ 1.36 $ 1.68 $ 0.22
Term (years) .37 .47 .43
Market yield 36.62 % 49.4 % 36.62 %
Probability of default 62.5 % 70 % 62.5 %
Recovery upon default 20 % 20 % 20 %
Volatility 182 % 177 % 182 %

6. Balance Sheet Details

Prepaid expenses and other current assets consisted of the following as of September 30, 2026 and December 31, 2025 (in thousands):

As of

September 30, 2026

As of

December 31, 2025

Prepaid expenses $ 579 $ 833
Tax receivable 160 -
Prepaid directors' and officers' insurance 970 990
Other receivables 125
Total prepaid expenses and other current assets $ 1,834 $ 1,823

Accrued expenses and other current liabilities consisted of the following as of September 30, 2026 and December 31, 2025 (in thousands):

As of

September 30, 2026

As of

December 31, 2025

Accrued professional fees $ - $ 388
Accrued legal contingency 9,626 9,594
HMRC payable 146 136
Investment payable 6,108 -
Accrued executive compensation and board of directors fees 543 -
Accrued other - 14
Total accrued expenses and other current liabilities $ 16,423 $ 10,132
15

7. Convertible Notes Payable

A.G.P. Convertible Note

A.G.P was a financial advisor to both Murphy Canyon Acquisition Corp. ("MURF") and Old Conduit in connection with the merger transaction (the "merger"). Upon the completion of the Merger, A.G.P.: (i) received a cash fee of $6.5 million, less than one share of Common Stock, and warrants to purchase less than one share of Common Stock pursuant to its engagement agreement with Old Conduit entered into on August 2, 2022, and (ii) agreed to defer payment, to be paid in the future under certain circumstances by a date no later than March 21, 2025, of $5.7 million of fees plus annual interest of 5.5% (the "Deferred Commission Payable") as a result of its engagement for MURF's IPO. During the nine months ended September 30, 2025, the Company reached an agreement with A.G.P. to waive all previously accrued interest. As such, the Company removed accrued interest of $0.4 million and recorded other income of $0.4 million during the nine months ended September 30, 2025.

On November 25, 2024, the Company issued to A.G.P. the A.G.P. Convertible Note in the principal amount of $5.7 million to evidence A.G.P.'s currently owed Deferred Commission Payable, at which time the Deferred Commission Payable balance was removed. Unless earlier converted as specified in the Convertible Note, the principal amount, plus all accrued but unpaid interest, was due on November 25, 2025 (the "Maturity Date"). The convertible promissory note accrued interest at 5.5% per annum.

During the three months ended June 30, 2026, the holder of the A.G.P. Convertible Note converted the remaining principal and interest into 250 shares of the Company's Common Stock. Prior to the conversion the A.G.P. Convertible Note was overdue but not considered to be in default by either party.

During the nine months ended September 30, 2026, the holder of the A.G.P. Convertible Note converted $2.4 million of principal and interest into 255 shares of the Company's Common Stock.

During the three months ended March 31, 2025, the holder of the A.G.P. Convertible Note converted $0.4 million of principal and interest into one share of the Company's Common Stock. As of March 31, 2025, the Company's Common Stock price was trading below the Conversion Price Floor. For the purpose of the March 31, 2025 conversion, the Company waived the Conversion Price Floor and allowed A.G.P. to convert at the prior trading days closing stock price. Upon conversion, the Company recorded a $0.2 million loss on the change in fair value based on the difference between (i) the fair value of the Common Stock issued and (ii) the percentage of total principal and interest converted (6.54%), multiplied by the December 31, 2024 valuation of $3.0 million.

On April 11, 2025, April 16, 2025, June 2, 2025, June 17, 2025, June 26, 2025 and September 29, 2025, the holder of the A.G.P. Convertible Note converted $ 0.5 million, $0.8 million, $0.1 million, $0.2 million, $0.2 million and $0.3 million of principal and interest all into less than one share of the Company's Common Stock. As of April 16, 2025, the Company's Common Stock price was trading below the Conversion Price Floor. For the purpose of the April 16, 2025 conversion, the Company waived the Conversion Price Floor and allowed A.G.P. to convert at the April 16, 2025 closing stock price.

On May 29, 2026, the holder of the A.G.P. Convertible Note converted $1.1 million of principal and interest into 227 shares of the Company's Common Stock and the A.G.P. Convertible Note was considered repaid in full.

For the three months ended September 30, 2025, the Company recorded a $0.1 million loss in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $0.1 million.

For the nine months ended September 30, 2026, the Company recorded a $0.1 million loss in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $33,000. For the nine months ended September 30, 2025, the Company recorded a $0.1 million gain in the change in fair value of the A.G.P. Convertible Note and interest expense of approximately $0.2 million.

As of September 30, 2026, there was no outstanding principal and interest remaining on the A.G.P. Convertible Note.

16

Ascent Note

On March 3, 2026, the Company issued to Ascent a convertible promissory note, defined above as the Ascent Note, with an aggregate principal amount of $0.6 million, with the Company receiving cash proceeds, net of discounts and fees, of $0.5 million. The Ascent Note had a maturity date of four months from the date of issuance and carried interest at a rate of 10% annually, which is payable monthly from the issuance date of the Note until the sooner of the maturity date or the date the Ascent Note is fully repaid or converted into shares of the Company's Common Stock.

On May 15, 2026, the Company and Ascent entered into an amendment (the "Note Amendment") to Ascent Note, originally issued on March 3, 2026. Pursuant to the Note Amendment, 90% of the proceeds raised by the Company in any debt or equity financing or capital-raising transaction, including pursuant to the ELOC, may be retained by the Company, with the remaining 10% required to go towards payment of amounts due under the Ascent Note.

At any time prior to the full payment of the convertible promissory note, Ascent, at its sole discretion, could have elected to have all or any portion of the outstanding principal amount and all interest accrued converted into shares of the Company's common stock, at a conversion price equal to the lower of the closing price of the Company's Common Stock on the date shareholder approval is obtained, which has not yet occurred, or the dollar volume-weighted average price of the Company's Common Stock for the five trading days immediately preceding the date of such delivery. The conversion price is subject to change, proportionate to any stock splits that may occur. The conversion of the convertible promissory could not have occurred prior to the Company having sufficiently authorized shares of common stock to permit the entire conversion of the convertible promissory note. In addition, the conversion of the convertible promissory note could also not have occurred prior to receipt of stockholder approval to provide for such conversion of the convertible promissory note, and subsequent issuance of the Company's common stock, pursuant to the stockholder approval rules under the rules and regulations of The Nasdaq Stock Market. Further, following Ascent's ability to convert the convertible promissory note, if at all, Ascent will not be entitled to receive the Company's common stock upon conversion, if such conversion would result in Ascent owning greater than 9.99% of the Company's then currently outstanding common stock. Ascent was also entitled to resale registration rights as identified within the convertible promissory note.

During June 2026, with funds received from the J.J Astor Note (see below), the Company repaid $0.4 million of principal and interest against the Ascent Note. No principal or interest remained following the repayment and the Ascent note is considered settled by both parties.

During the nine months ended September 30, 2026, the Company recognized approximately $11,000 of contractual interest expense related to the Ascent Note. See Note 3 and Note 5 for further discussion of the Ascent Note.

J.J. Astor Notes

First J.J. Astor Convertible Note

On June 11, 2026, the Company issued a senior secured convertible promissory note to J.J. Astor & Co., defined above as the J.J. Astor Note, in the principal amount of $2.0 million with proceeds of $1.5 million, funded in two tranches. On June 30, 2026, the Company amended the agreement to close the second tranche of the loan. The J.J. Astor Note had a maturity date of December 18, 2026, with repayment terms of twenty-four equal weekly installment payments of $82,000 to commence on July 10, 2026.

Repayments may be paid in cash or, at the option of the Company commencing six months following the closing, in shares of the Company's Common Stock, at a conversion price equal to the greater of: (a) Ninety Percent (90%) of the lowest volume-weighted average price ("VWAP") of the Company's Common Stock over the ten consecutive trading days immediately preceding the date of conversion; or (b) the applicable Nasdaq Floor Price (the "Conversion Price Formula"). The conversion price is subject to further adjustments if the Company's Common Stock is trading below the Nasdaq price floor.

Additionally, the Company issued to J.J. Astor & Co., common stock purchase warrants to purchase 182 shares of the Company's Common Stock at an exercise price of $3,600.00 per share. The Warrants became exercisable on the effective date of stockholder approval of the issuance of the Warrant Shares and expire five years from the date thereof.

17

At any time prior to the full payment of the convertible promissory note, J.J., at its sole discretion, can elect to have all or any portion of the then-outstanding balance converted into shares of the Company's common stock, at a conversion price equal to the greater of 90% of the lowest volume-weighted average price of the Company's common stock over the ten consecutive trading days immediately preceding the date of conversion or the applicable floor price subject to Nasdaq Rule 5635(d).

Second and Third Amendment to First J.J. Astor Convertible Note

On July 31, 2026, the Company entered into a second amendment to the J.J. Astor Note discussed in Footnote 7. The Company failed to make three scheduled weekly installment payments of $82,000 due July 17, July 24, and July 31, 2026, totaling $246,000, and had not filed the required resale registration statement by its deadline.

Under this amendment, the lender agreed to treat these matters as an accommodation, rather than an event of default, but expressly reserved all rights if any future payment default occurs.

In connection with the accommodation, the total principal balance was increased by a $378,000 restructuring premium, to a total amended principal balance due to J.J. Astor of approximately $2.3 million and increased the default interest rate from 19% to 24% per annum upon any future event of default. The amendment reschedules repayment into 23 weekly installments of approximately $104,000, that commenced on August 19, 2026 through a new maturity date of January 20, 2027. The amendment also updated the registration statement filing requirement deadline to August 31, 2026, with any further delay constituting an immediate event of default.

It increases the required share of the Company's ATM program net proceeds from offerings due to J.J. Astor to 90% and requires the Company to effect weekly ATM program financing and generate net proceeds of at least $115,000 per week.

The amendment also revised the note's conversion terms to a conversion price equal to the greater of 70% of the lowest volume-weighted average price of the Company's common stock over the twenty consecutive trading days immediately preceding the date of conversion or the applicable floor price subject to Nasdaq Rule 5635(d). and requires the Company to obtain stockholder approval to increase authorized shares and reserve shares equal to 200% of the amounts issuable upon conversion in full of the amended principal balance.

On August 3, 2026, the Company and J.J. Astor & Co. entered into a third amendment to the Amended Note and Amended Loan Agreement (the "Third Amendment"). Pursuant to the Third Amendment, J.J. Astor advanced $0.2 million to the Company, subject to fees, and increased the outstanding principal balance of the Amended Note to approximately $2.5 million. Additionally, the Company has also issued J.J. Astor warrants to purchase up to 75 shares of the Company's common stock at a purchase price of $3,600.00, in the same form of warrant issued to on June 11, 2026. Moreover, the definition of "Floor Price" in the Amended Note and the Amended Loan Agreement was adjusted to equal twenty percent of the lowest volume-weighted average price of the Company's common stock during the twenty (20) consecutive trading days immediately preceding the date the Floor Price adjusts, which adjusts every six months commencing December 11, 2026.

The issuance of any or all of the shares under the J.J. Astor Note, including the shares issuable upon exercise of the warrants issued in connection therewith, in the aggregate in excess of 19.99% of the current number of outstanding shares of common stock of the Company is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC, to the extent required by such rules and regulations ("Stockholder Approval").

On August 28, 2026, at the Company's annual meeting of stockholders, stockholders approved the issuance of the 257 warrant shares upon exercise of all 257 outstanding warrants upon conversion of the note.

18

Second J.J. Astor Convertible Note

On August 31, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. (the "August 2026 Note"), in the principal amount of $541,620. The Company received $401,000 before deducting closing fees, with net proceeds of $375,000 funded to the Company. On September 4, 2026, the August 2026 Note was repaid in full and is no longer outstanding. In connection with the issuance of the August 2026 Note, the Company also issued to J.J. Astor & Co. warrants to purchase 474 warrant shares at an exercise price of $845 per share. The Warrants are exercisable immediately upon issuance and will expire five years after the issue date.

The issuance of Warrant Shares in excess of 19.99% of the current number of outstanding shares of Common Stock is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC, to the extent required by such rules and regulations ("Stockholder Approval"). The Company agreed to convene a stockholder meeting to obtain such approval if requested by the Lender, but no later than October 31, 2026.

Third J.J. Astor Convertible Note

On September 14, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. (the "September 2026 Note"), in the principal amount of $2.1 million. The Note matures on March 1, 2027 and is payable in twenty-four weekly installments of $89,000 starting on September 21, 2026. The Note was issued pursuant to the first Loan Agreement, dated as of June 11, 2026, as amended and restated to date between the Company, and J.J. Astor & Co. The Company received $1.6 million before deducting closing fees, with net proceeds of $1.5 million funded to the Company. On September 17, 2026, the September 2026 Note was repaid in full and is no longer outstanding.

Additionally, the Company issued to the J.J. Astor & Co. common stock purchase warrants to purchase 6,937 shares of the Company's common stock at an exercise price of $125.00 per share. The Warrants are exercisable upon issuance and will expire five years after the issue date.

See Note 3 and Note 5 for further discussion of the J.J. Astor Notes.

The J.J. Astor Notes are accounted for under the fair value option elected pursuant to ASC 825 and were initially recognized at its estimated fair value. As a result, the original issue discount and lender-related fees were reflected in the initial fair value measurement and were not separately recognized as debt discounts or debt issuance costs. The Company subsequently remeasures the J.J. Astor Notes to fair value at the reporting date, with changes in fair value recognized in earnings, except for the portion attributable to instrument-specific credit risk, which is recognized in other comprehensive income.

During both the three and nine months ended September 30, 2026, the Company recognized $0.1 million in interest expense related to the J.J. Astor Note. As of September 30, 2026, the outstanding principal balance of the J.J. Astor Note was $2.7 million.

8. Research and Development Expense

Sarborg Service Agreement - Related Party

On December 12, 2024, the Company entered into a Services Agreement (the "Sarborg Service Agreement") with Sarborg Limited ("Sarborg"), a Cayman Islands company and related party of the Company. See Note 13 for further reference to the relationship between the Company and Sarborg. Under the terms of the Sarborg Service Agreement, Sarborg will provide algorithmic and cybernetic technology services to CDT, including the development of decision-support tools and advanced cybernetic systems tailored to enhance CDT's decision-making processes and maximize the value of its pharmaceutical asset portfolio.

The Sarborg Service Agreement has an initial term of 12 months, which commenced on the effective date, and may be renewed or extended upon mutual written agreement of the parties. Either party may terminate the Sarborg Service Agreement for any reason upon 90 days' written notice or immediately upon written notice if the other party breaches any material term of the Sarborg Service Agreement and fails to cure such breach within thirty days or becomes insolvent, files for bankruptcy, or is placed under the control of a receiver, trustee, or similar authority.

19

The Sarborg Service Agreement includes provisions for the ownership and use of intellectual property. Sarborg will own its pre-existing intellectual property rights, including proprietary tools and methodologies used in the performance of the services. CDT will own all deliverables resulting from the services performed by Sarborg under the Sarborg Service Agreement.

The Sarborg Service Agreement provides Sarborg with registration rights for any Common Stock of CDT that Sarborg receives as consideration under the Sarborg Service Agreement. In such event, CDT will use commercially reasonable efforts to (i) file a registration statement covering the resale of the Common Stock within 60 days after the issuance; and (ii) ensure that such registration statement becomes effective within 90 days after filing. This Agreement also includes confidentiality obligations, representations and warranties, indemnification, limitation of liability, and insurance requirements.

In consideration of the services, CDT agreed to pay Sarborg an initial cash payment of $0.2 million and $0.2 million payable through the issuance of 1 share of Common Stock, determined by the closing price on the day preceding the execution of the Sarborg Service Agreement. The initial cash payment of $0.2 million was made on December 20, 2024, and the share of Common Stock was issued on January 17, 2025. Further milestone payments payable in conjunction with the achievement of certain milestones over the term of the Sarborg Service Agreement, totaling up to $1.8 million. Sarborg was reimbursed for pre-approved, necessary, and reasonable out-of-pocket expenses directly incurred in connection with the performance of the services.

The Company made an initial cash payment of $0.2 million and issued 1 share of Common Stock in connection with the Sarborg Service Agreement. These costs were capitalized as prepaid expenses and are being amortized to research and development expense over the initial term of the agreement. No research and development expense was recorded during the three and nine months ended September 30, 2026. For the three and nine months ended September 30, 2025, the Company recorded amortization expense of $0.1 million and $0.3 million, respectively, in research and development expenses in the consolidated statement of operations and comprehensive loss. No prepaid balance remained as of September 30, 2026.

Under the Sarborg Service Agreement, the Company is provided with a dashboard that is utilized for both the Company's existing and future asset portfolio. Specifically, the dashboard includes a clinical trial monitoring functionality and a dynamic pharmaceutical patent landscape module to assess both the Company's current assets undergoing clinical trials and delisted patents in the marketplace that may be overlooked by other market participants. These features will be used by management to monitor progress, assess trial status, identify new opportunities, and support decision-making across all current and future development programs. The Company assessed the guidance in ASC 730 and determined that $0.4 million of total cost of the acquired asset should be capitalized as the dashboard is considered a purchased diagnostic asset with alternative future use. Management determined that the dashboard has a useful life of two years. The dashboard was placed in service on March 18, 2025. During the three and nine months ended September 30, 2026 the Company recorded $0.1 million and $0.2 million, respectively, in amortization expense. During both the three and nine months ended September 30, 2025, the Company recorded $0.1 million in amortization expense.

All other costs under the Sarborg Service Agreement shall be expensed as incurred and recorded within research and development expense in the consolidated statement of operations and comprehensive loss, as the services are designed to aid in the Company's research and development activities.

There was $0.1 million in payments made to Sarborg related to the Sarborg Service Agreement during both the three and nine months ended September 30, 2026. During the three and nine months ended September 30, 2025, Sarborg was paid $0.2 million and $2.0 million, respectively, for completed milestones under the Sarborg Service Agreement. The Company recorded $0.1 million and $1.7 million in expense within research and development expense in the condensed consolidated statement of operations and comprehensive income loss for the three and nine months ended September 30, 2025, respectively.

20

Sarborg Additional Agreement - Related Party

Effective March 31, 2025, the Company entered into an additional license and use agreement (the "Sarborg Additional Agreement") with Sarborg, a related party, covering certain additional deliverables and incorporating a new scope of work focused on analysis of the Company's acquired AstraZeneca assets. The term of the Sarborg Additional Agreement was for six months and provides for the payment, in aggregate, of $2.0 million, which includes an up-front license fee for the term of such agreement, in cash or stock at the Company's election at the closing price on the day preceding the effective date of such agreement. On March 31, 2025, the Company prepaid $1.65 million of the Sarborg Additional Agreement through the issuance of less than one share of Common Stock. The Company recorded the share issued under the Sarborg Additional Agreement at their fair value, as determined by the closing price of the Company's Common Stock on March 30, 2025, $667,467.50. Effective June 24, 2025, the term was extended to be 12 months from the effective date of the Sarborg Additional Agreement at no additional cost to the Company. Effective October 1, 2025, the term was extended to be 12 months from the previous extension date of May 2, 2025 to extend the term of the license to March 31, 2027 at no additional cost to the Company. The Company recorded the fair value of $1.5 million as prepaid within the consolidated balance sheet as of March 31, 2025. For the three and nine months ended September 30, 2026, the Company recognized $0.1 million and $0.4 million, respectively, in expense related to the amortization of the Sarborg Additional Agreement. During the three and nine months ended September 30, 2025, the Company recorded research and development expense of $0.4 million and $1.3 million, respectively, related to the Sarborg Additional Agreement.

First Addendum to Sarborg Additional Agreement - Related Party

Effective July 1, 2025 the Company entered into an Addendum (the "First Addendum") to the Additional Agreement with Sarborg. Under the terms of the Addendum, Sarborg expanded the scope of the Additional Agreement to provide external analysis of third-party pharma companies assets suitable for drug re-purposing and evaluate the efficacy of the assets utilizing Conduit's license to Sarborg's machine learning platform. The total consideration for the additional services was $0.3 million. The Company paid $0.3 million during the three and nine months ending September 30, 2025 and it is included in the consolidated statement of operations and comprehensive loss.

Second Addendum to Sarborg Additional Agreement - Related Party

Effective August 11, 2025 the Company entered into Addendum 2 (the "Second Addendum") to the Additional Agreement with Sarborg. Under the terms of the Second Addendum, Sarborg expanded the scope of work to integrate a Cryptocurrency AI Agent, developed specifically for identifying, forecasting and recommending digital currencies into CDT Equity's operations as part of its treasury strategy.

The initial consideration for the expanded scope of work was $0.2 million, which was paid during the three and nine months ended September 30, 2025 and included in the consolidated statement of operations and comprehensive loss. The Company agreed to pay further consideration of $0.2 million in cash or shares, at the Company's sole discretion, at such time as the Company invests more than $0.6 million in cryptocurrency as part of its treasury strategy.

Sarborg Second Additional Agreement - Related Party

Effective January 2, 2026, the Company and Sarborg entered into the Second Additional Agreement (the "Second Additional Agreement"). The Second Additional Agreement had a term of six weeks and can be renewed upon the mutual written agreement of both parties. Total consideration payable from the Company to Sarborg totals $0.4 million, with $0.2 million due, and paid, upon execution of the Second Additional Agreement and the remaining balance due as mutually agreed by the parties. During the three and nine months ended September 30, 2026, the Company recorded nil and $0.4 million, respectively, of expense related to the Second Additional Agreement.

In total, the Company recorded $0.2 million and $0.8 million of research and development expense and amortization for the three and nine months ended September 30, 2026, respectively, all of which related services and costs incurred through the Sarborg Additional Agreement and the Sarborg Second Additional Agreement, collectively.

In total, the Company recorded $1.2 million and $3.6 million of research and development expense and amortization during the three and nine months ended September 30, 2025, respectively, all of which related to services and costs incurred through the Sarborg Service Agreement, Sarborg Additional Agreement, First Addendum and the Second Addendum, collectively.

21

Manoira Joint Development Agreement

On June 3, 2025, the Company entered into a joint development agreement (the "Joint Development Agreement") with Manoira Corporation ("Manoira") for a term of one year, which will be automatically renewed for successive one-year terms unless advance termination notice is provided in accordance with the terms of the Joint Development Agreement. Manoira is an entity controlled by Dr. Andrew Regan, of which he is the sole director, and is therefore considered a related party of the Company. Refer to Note 13 for additional details.

Pursuant to the Joint Development Agreement, CDT granted Manoira a non-exclusive, non-transferable, non-sublicensable, fully paid-up, royalty-free license to the intellectual property rights related to the pharmaceutical compounds known individually and together as AZD1656 and AZD5658 (the "CDT Assets"). Manoira will evaluate the CDT Assets' applicability in animal health, explore veterinary market opportunities, and provide data from the evaluations to inform CDT's human clinical programs. The license does not grant Manoira the right to distribute, market, promote or sell the products or services that are related to or incorporate the CDT Assets.

Effective June 3, 2025, in exchange for the approximate $0.5 million of consideration to be paid by CDT under the Joint Development Agreement, CDT issued to Manoira less than one share of its Common Stock, (the "Consideration Shares") valued at the closing price of the Common Stock immediately preceding execution of the Joint Development Agreement. The Company recorded the shares issued under the Joint Development Agreement at their fair value, as determined by the closing price of the Company's Common Stock on June 3, 2025, $197,000. The Company recorded the fair value of $0.4 million as prepaid within the unaudited condensed consolidated balance sheets. During the nine months ended September 30, 2026, the Company recorded nil of amortization expense as no significant work was performed by Manoira in relation to the Joint Development Agreement. During the three and nine months ended September 30, 2025, the Company recorded $0.1 million amortization expense for research and development activities provided to date.

Through the nine months ended September 30, 2026, the Company did not record any amortization expense related to research and development activities.

9. Share Based Compensation

2023 Stock Incentive Plan

On September 22, 2023, in connection with the Merger, the Company adopted the CDT Equity Inc. 2023 Stock Incentive Plan (the "2023 Plan"). The 2023 Plan became effective upon the closing of the Merger. The 2023 Plan initially provided for the issuance of up to 1 share of Common Stock. Pursuant to the 2023 Plan's "evergreen" provision, on February 6, 2025 and January 10, 2024, the Company increased the number of shares of Common Stock available for issuance under the 2023 Plan by less than one share. The number of authorized shares will automatically increase on January 1, 2026 and continuing annually on each anniversary thereof through (and including) January 1, 2033, equal to the lesser of (i) 5% of the shares of Common Stock outstanding on the last day of the immediately preceding fiscal year and (ii) such smaller number of shares of Common Stock as determined by the Board or the applicable committee of the Board. The 2023 Plan allows for awards to be issued to employees and non-employee directors in the form of options, stock appreciation rights, restricted stock, restricted stock units ("RSUs"), performance stock units, dividend equivalents, other stock-based, or other cash-based awards.

On August 5, 2025, at the Company's 2025 Annual Meeting of Stockholders, stockholders approved an amendment and restatement of the Company's 2023 Stock Incentive Plan (as amended, the "Amended 2023 Stock Incentive Plan") to authorize an additional 2 shares of Common Stock for awards under the Amended 2023 Stock Incentive Plan. The Amended 2023 Stock Incentive Plan was recommended and approved by the Board on July 8, 2025.

On January 1, 2026, in accordance with the 2023 Plan, the number of authorized shares under the 2023 plan increased by 1 share. As of September 30, 2026, there was 1 share of Common Stock available for issuance under the 2023 Plan.

22

Stock Options

The Company did not grant stock options during the three and nine months ended September 30, 2026. The Company granted 1 option during the nine months ended September 30, 2025.

The Company accounts for forfeitures as they occur, which may result in the reversal of compensation costs in subsequent periods as the forfeitures arise.

The following table summarizes stock option activity for the 2023 Plan:

Number of

Options

Weighted

Average

Exercise

Price

Weighted

Average

Remaining

Contractual

Term

(years)

Aggregate

Intrinsic

Value

(in thousands)

Outstanding at December 31, 2025 1 $ 97,576,420 8.47 $ -
Granted - - - -
Cancelled/forfeited - - - -
Exercised - - - -
Outstanding at September 30, 2026 1 $ 97,576,420 7.72 $ -
Exercisable 1 $ 57,859,200 7.85 $ -
Unvested - $ - - $ -

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of the Company's Common Stock for those options that had exercise prices lower than the fair value of the Company's Common Stock. As of September 30, 2026, the total compensation cost related to non-vested option awards not yet recognized was $0.6 million with a weighted average remaining vesting period of 0.73 years.

For the three and nine months ended September 30, 2026, there was $0.2 million and $0.6 million, respectively, and for the three and nine months ended September 30, 2025, there was $1.6 million and $2.0 million, respectively, recognized for stock-based compensation expense within general and administrative expenses on the unaudited condensed consolidated statements of operations and comprehensive loss.

Board of Directors Shares

On March 30, 2025, certain non-employee directors elected to receive their unpaid cash retainers due through the period ended June 30, 2025, under the Director Compensation Program, in the form of fully vested shares of Common Stock. In total, $0.1 million of unpaid retainers was settled through the issuance of less than one unregistered share of Common Stock (the "Retainer Shares"). The Company recorded the Retainer Shares at their fair value, as determined by intraday share prices of the Company's Common Stock on March 31, 2025. In relation to the Retainer Shares, the Company recorded nil and $0.1 million of expense within general & administration expense in the unaudited condensed consolidated statement of operations and comprehensive loss during the three and nine months ended September 30, 2025, respectively.

On April 16, 2025, less than one share of the Company's Common Stock was issued to a non-employee director. The share was approved by the Board as a one-time award for services provided to the Company. The Company recorded the share at its fair value, as determined by the Company's closing share price on the prior trading day, April 14, 2025. The Company recorded nil and $0.1 million within general & administration expense in the condensed consolidated statement of operations and comprehensive loss during the three and nine months ended September 30, 2025 in relation to the award.

On August 5, 2025, the Company approved and granted equity awards to non-employee directors under the 2023 Plan, in the form of 1 option to purchase the Company's Common Stock, which vested immediately upon issuance. The Company recorded compensation expense based on the weighted-average fair market value per share of the awards on the grant date of $0.1 million during both the three and nine months ended September 30, 2025

23

Cryptocurrency Consulting

Effective June 27, 2025, the Company entered into an agreement (the "Crypto Consulting Agreement") for a third-party consultant to evaluate and advise on the potential adoption of a part cryptocurrency treasury reserve strategy. The Crypto Consulting Agreement contains a term of 12 months and required compensation of $0.2 million in the form of shares of the Company's Common Stock. On June 27, 2025, the Company issued less than one share of Common Stock valued at the closing price for the previous day. For both the three and nine months ended September 30, 2025, the Company recorded $0.1 million of general and administrative expense within the unaudited condensed consolidated statements of operations and comprehensive loss related to the amortization expenses.

Management Shares

Effective September 19, 2025, one share of the Company's Common Stock was issued to the Company's former CEO and CFO, respectively. The shares were approved by the Board as a one-time award for services provided to the Company. The Company recorded the shares at their fair value, as determined by the Company's closing share price on the prior trading day, September 18, 2025. The Company recorded $1.1 million within general & administration expense in the condensed consolidated statement of operations and comprehensive loss during the three and nine months ended September 30, 2025 in relation to the shares.

Restricted Stock Units

By unanimous written consent of the Board, on August 12, 2025 the Company granted 2 Restricted Stock Units to three Board members for past services performed. The RSUs fully vested on the grant date and the expense was recorded as a general and administrative expense in the unaudited condensed consolidated statement of operations and comprehensive loss based upon the CDT closing share price on the date of the grants.

NJS Foresight Bio-Advisory Variation Agreement

On July 30, 2026, the Company agreed to a variation of the previous agreement with NJS Foresight Bio-Advisory ("NJS") to compensate NJS with an additional $0.1 million, payable with 67 shares of the Company's Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance.

Thesprogen Variation Agreement

On July 30, 2026, the Company agreed to a variation of the previous agreement with Thesprogen to compensate Thesprogen with an additional $0.1 million, payable with 67 shares of the Company's Common Stock for services performed to date. All shares are fully vested, fully paid and nonassessable upon issuance.

Maxim Group LLC Amendment to Letter Agreement

On July 29, 2026, the Company and Maxim entered into an amendment to the original agreement dated February 6, 2026. The amendment updated the first sentence of section 3(b) of the original agreement which stated the Company will issue Maxim or its designees 26 shares of the Company's Common Stock is replaced with the Company will issue Maxim or its designees 51 shares of the Company's Common Stock in the amendment to the original agreement.

24

EX-ANIMO LTD Consulting Agreement

On July 24, 2026, the Company and EX ANIMO Ltd ("EX-ANIMO") entered into a consulting agreement. The Company agreed to issue $0.1 million of the Company's Common Stock, totaling 64 shares, in exchange for consulting services to be rendered.

10. Income Taxes

On July 4, 2025, the United States Congress passed the budget reconciliation bill H.R. 1, known as the One Big Beautiful Bill Act ("OBBBA"). Key provisions include the repeal of Section 174 R&D capitalization requirements, the extension of 100% bonus depreciation, restoration of the Section 163(j) interest limitation to an EBITDA basis, and the introduction of a 1% charitable contribution deduction floor. As of September 30, 2026, the immediate expensing of R&D costs under Section 174, the continuation of 100% bonus depreciation, and the restoration of the EBITDA-based Section 163(j) limitation are expected to decrease cash taxes in the short term and generate a federal net operating loss. These changes did not have a material impact on the Company's effective tax rate.

For the nine months ended September 30, 2026, and 2025, the Company's effective tax rate was 0.0% due to the current year tax loss and valuation allowance established against the Company's net deferred tax assets, and due to operating in a zero tax jurisdiction.

11. Common Stock and Preferred Stock

At-the-Market Offering

On October 23, 2024, the Company entered into the Sales Agreement with A.G.P. (the "Sales Agreement") relating to the sale of shares of the Company's Common Stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of our Common Stock having an aggregate offering price of up to $23.9 million from time to time through A.G.P., acting as our sales agent or principal.

The compensation to A.G.P. for sales of Common Stock sold pursuant to the Sales Agreement is equal to 3.0% of the gross proceeds of any shares of Common Stock sold under the Sales Agreement.

On April 2, 2026, the Company filed an amendment ("Amendment No. 6") to prior prospectus filings with the Securities and Exchange Commission to disclose that the Company may offer and sell shares of our Common Stock having an aggregate offering price of up to $76.1 million from time to time through A.G.P., acting as our sales agent or principal.

During the nine months ended September 30, 2026, the Company sold 46,801 shares of the Company's Common Stock through the Sales Agreement and received net proceeds of $5.6 million.

During the nine months ended September 30, 2025, the Company sold 7 shares of the Company's Common Stock and received proceeds of $18.0 million, net of commissions payable to A.G.P. of $0.6 million.

Investment in Sarborg

As discussed in Note 4, on February 19, 2026, the Company made an investment in Sarborg to acquire 20% of the outstanding shares of Sarborg from its investors. The Company issued Sarborg 4 shares of the Company's Common Stock on February 18, 2026, totaling $0.6 million as a portion of the total consideration transferred for the investment. In connection with the investment in Sarborg, the Company also issued Pre-Funded Warrants to purchase up to 879 shares of the Company's Common Stock. The Pre-Funded Warrants mirror the terms of the Pre-Funded Warrants issued to Corvus and are exercisable at any time on or after shareholder approval (the "Shareholder Approval Date") and remains outstanding until exercised in full. The exercise price is considered nominal, and the holder is only required to pay the exercise price upon exercise to receive the underlying common shares.

25

On March 19, 2026, all 879 of the pre-funded warrants were exercised through a cashless exercise into 879 shares of the Company's Common Stock.

On July 30, 2026, the Company entered into a Securities Purchase Agreement with shareholders of Sarborg. The investors of Sarborg agreed to sell to the Company, and the Company agreed to acquire from the shareholders of Sarborg, an aggregate of 270 shares of Sarborg, representing approximately 4.76% of the outstanding shares of Sarborg. As consideration for the purchase, the Company agreed to issue to the shareholders of Sarborg pre-funded warrants to purchase up to 24,263 shares of the Company's Common Stock.

On August 28, 2026, following the receipt of stockholder approval, all of the pre-funded warrants were exercised on a cashless basis, and the Company issued an aggregate of 24,258 shares of the company's common stock.

12. Net Loss Per Share Attributable to Common Stockholders

Potentially dilutive securities (upon conversion) that were not included in the diluted per share calculations because they would have been anti-dilutive were 7,668 and 1 as of September 30, 2026 and September 30, 2025, respectively.

13. Related Party Transactions

Corvus Capital Limited

Corvus Capital Limited ("Corvus") is a significant investor in the Company through subscribing to 1 common share prior to the closing of the Merger on September 22, 2023. The share held by Corvus on the closing date of the Merger were exchanged for shares of Conduit Pharmaceuticals Inc. common stock. The former Chief Executive Officer of the Company, who is currently a significant stockholder of the Company, is also the principal owner of Corvus. Occasionally, Corvus provides advisory services to the Company and is paid a fee for the services. As of September 30, 2026, and December 31, 2025, no advisory fees were due to Corvus.

For the three and nine months ended September 30, 2026, the Company incurred director travel expenses of $0.1 million and $0.6 million, respectively. For the three and nine months ended September 30, 2025, the Company incurred director travel expenses of $0.2 million and $0.5 million, respectively.

On August 31, 2026, the former Chief Executive Officer of the Company notified the Company and the Board of his resignation from both the Board and position of Chief Executive Officer effective immediately. In connection with the resignation, the Company agreed to pay the former Chief Executive Officer a severance payment in the amount of $0.3 million, payable in six monthly installments of $50,000. As of September 30, 2026, no payments were made towards the severance amount and the $0.3 million was accrued as a short-term liability as the balance is payable within one year of the severance notification date.

Appointment of Chief Executive Officer

On August 31, 2026, in conjunction with the resignation of the former Chief Executive Officer, as discussed above, the Company appointed James Bligh to serve as Chief Effective Officer effective immediately. James Bligh will continue to serve as the Company's Chief Financial Officer until a successor is named.

Nirland

On August 6, 2024, the Company entered into the August 2024 Nirland Note with Nirland, a related party of the Company. The Company determined that Nirland was a related party due to Nirland's ownership interest in the Company concurrently with the execution of the August 2024 Nirland Note. Additionally, on October 28, 2024, the Company issued the October 2024 Nirland Note to Nirland, and on October 31, 2024, the Company and Nirland amended the August 2024 Nirland Note, and on November 22, 2024, the Company and Nirland amended the August 2024 Nirland Note for a second time. During the nine months ended September 30, 2025, the Company repaid Nirland through conversions and a final cash payment.

26

Sarborg

On December 12, 2024 and March 31, 2025, the Company entered into the Sarborg Service Agreement and the Sarborg Additional Agreement, respectively. During 2025, the Company and Sarborg also executed the First Addendum and Second Addendum to the Sarborg Additional Agreement. On January 2, 2026 the Company and Sarborg executed the Sarborg Second Additional Agreement.

Sarborg is considered to be a related party of CDT, as Dr. Andrew Regan, the Company's former Chief Executive Officer and current stockholder of the Company, also sits on the board of directors of Sarborg and is a shareholder of Sarborg through his ownership of Corvus, Chele Chiavacci Farley, a director of CDT is also a shareholder of Sarborg and Ulrik Olsen, a director of CDT is also a shareholder of Sarborg. In addition, the company owns 22.74% of the outstanding shares of Sarborg's common stock.

During the three months ended September 30, 2026 and 2025, the Company recorded $0.2 million and $1.2 million, respectively, as research and development expense related to the Sarborg arrangements. During the nine months ended September 30, 2026 and 2025, the Company recorded $0.8 million and $3.6 million, respectively, as research and development expense related to the Sarborg arrangements.

On March 31, 2025, the Company issued 1 fully vested unregistered shares of Common Stock to prepay amounts due under the Sarborg Additional Agreement. The shares had a fair value of approximately $1.5 million and were recorded as a prepaid asset within the unaudited condensed consolidated balance sheets. As of September 30, 2026 and December 31, 2025, the remaining prepaid balance was $0.3 million and $0.6 million, respectively. Refer to Note 8 for additional information regarding the Company's agreements with Sarborg. See Note 4 for discussion of the Company's investment in Sarborg.

Manoira

On June 3, 2025, the Company entered into a joint development agreement (the "Joint Development Agreement") with Manoira Corporation. Dr. Andrew Regan, a current significant stockholder of the Company, former Chief Executive Officer and former member of the Board, also is a director and controlling member of Manoira. Through the Joint Development Agreement, the Company and Manoira intend to jointly evaluate AZD1656, and any of its derivatives, as well as AZD5658, in animal health indications and produce transitional data to inform the Company's human clinical programs while exploring veterinary market opportunities. The Company delivered shares of the Company's Common Stock worth $0.5 million to Manoira as its contribution to the Joint Development Agreement, with Manoira bearing all subsequent costs incurred during the joint development period. During the nine months ended September 30, 2026 and 2025, there were no research and development expenses recorded in the unaudited condensed consolidated statement of operations and comprehensive loss. As of September 30, 2026, the Company has a $0.3 million prepaid expense related to the Joint Development Agreement recorded in the unaudited condensed consolidated balance sheet. As of December 31, 2025, the Company had a $0.3 million prepaid expense related to the Joint Development Agreement recorded in the consolidated balance sheet. Refer to Note 8 for additional details.

Investment in Pep'd SAFE Note

On August 25, 2026, the Company entered into a simple agreement for future equity (the "SAFE Note") with Pep'd Inc. ('Pep'd"). Pep'd is a related party of the Company as the Company's former Chief Executive Officer was the Chief Executive Officer of the Company and sole director of Pep'd at the time of the agreement. As consideration for entering into the SAFE Note, the Company agreed to pay Pep'd $0.1 million of cash consideration. As of September 30, 2026, the $0.1 million balance was not paid and was recorded as a current liability on the Company's condensed consolidated balance sheet. The $0.1 million was subsequently paid during October 2026.

27

14. Other Expense, net

The following table presents other income (expense), net, for the three and nine months ended September 30, 2026 and 2025 (in thousands):

For the three months ended September 30, For the nine months ended September 30,
2026 2025 2026 2025
Other income:
Unrealized foreign currency transaction gain $ - $ - $ 1 $ 27
Gain on change in fair value of derivative warrant liability 465 - 465 137
Gain on change in fair value of convertible notes payable - - - -
Interest income - 7 - 19
Gain on debt extinguishment - - - 278
Gain on waiver of accrued interest - - - 371
Gain on waiver of consideration payable for investment in related party 640 - 640 -
Research and development tax receivable 163 97 163 97
Gain on the issuance of shares for services - - - 70
Other 4 - 4 -
Total other income: 1,272 104 1,273 999
Other expense:
Loss on the change in fair value of convertible notes payable 450 126 1,183 3,001
Loss on the change in fair value of digital assets - 8 - 8
Interest expense 131 48 197 281
Loss on equity method investment 298 - 452 -
Loss on debt extinguishment 1,079 - 2,152 -
Other - 7 21 7
Total other expense 1,958 189 4,005 3,297
Total other expense, net $ (686 ) $ (85 ) $ (2,732 ) $ (2,298 )

15. Commitments and Contingencies

Legal Proceedings

The Company is subject to certain claims and contingent liabilities that arise in the normal course of business. While we do not expect that the ultimate resolution of any of these pending actions will have a material effect on our unaudited consolidated results of operations, financial position or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any legal action, pending or otherwise, does not become material in the future.

On September 7, 2023, following the merger between Conduit Pharmaceuticals Limited ("CPL") and Conduit Merger Sub, Inc., a Cayman Islands exempted company, Strand filed a claim in the Business and Property Courts of England and Wales claiming it was entitled to be paid the sum of $2 million and, as a result of the completion of the Business Combination, to be issued 1 share of the Company's Common Stock as a market value calculated by Strand of $65 million. The trial in this matter ended in October 2025, with a judgment finalized on December 16, 2025, in the amount of approximately $7 million, plus interest and repayment of a fraction of Strand's costs totaling $9.6 million. CDT is not a party to the CPL judgment.

Prior to the issuance of the judgment, the Company completed the sale of CPL to Corvus, pursuant to the Sale and Purchase Agreement. See Note 16 for further discussion of the sale of CPL in relation to the Strand litigation. In connection with the transaction, the Company obtained legal advice and structured the arrangement such that CPL retained the obligation associated with the Strand litigation following the sale on December 8, 2025. However, in accordance to the principles of consolidation as discussed in Note 3, the Company evaluated the accounting implications of the transaction, including the assessment of isolation, and concluded that the arrangement did not satisfy isolation of the Company from CPL. Accordingly, in connection with the judgment, Conduit Pharmaceuticals Limited recorded a $9.6 million litigation liability and it is included in the Company's consolidated balance sheet. To date, no legal action against the Company has commenced to enforce the judgment against the Company and the Company will continue to vigorously defend its position as it relates to the litigation with Strand.

28

Separately, during November and December 2024, the Company received a letter from St George Street Capital and formal complaints filed with the Intellectual Property Office claiming the Company was incorrectly assigned the US Application, and was not the correct owner, of the AZD 1656 co-crystal patent. In January 2025, Conduit issued a counter statement to the Intellectual Property Office disputing the claim filed by St George Street Capital. The litigation challenges the registration of the patent and the Company does not believe there to be any financial implications from the litigation. As of September 30, 2026, the damages sought by St George Street Capital are non-monetary and the potential contingency is not considered probable. As such, the Company has not accrued a loss contingency in the accompanying unaudited condensed consolidated financial statements. We intend to vigorously defend against these IP claims. Regardless of the eventual outcome, the patent dispute may impact our business due to, among other things, legal costs and the diversion of the attention of our management.

Leases

The Company has a lease agreement for approximately 2,100 square feet of space in Cambridge, England, with a term from March 2024 to January 2027. As of September 30, 2026, the Company has a right-of-use asset of approximately $29,000 and a corresponding lease liability of approximately $9,000 recorded on the unaudited condensed consolidated balance sheets. The full balance of the lease liability is classified as short-term. As of September 30, 2026, the Company's future minimum lease payments remaining is immaterial.

16. Warrants

Warrants - Corvus and Sarborg

In connection with the Sale and Purchase Agreement with Corvus, the Company issued pre-funded warrants to purchase up to 29 shares of the Company's Common Stock at an exercise price of $12.50 per pre-funded warrant. On March 24, 2026, following receipt of stockholder approval, all 29 of the pre-funded warrants were exercised through a cashless exercise into 29 shares of the Company's Common Stock.

In connection with the investment in Sarborg, the Company issued pre-funded warrants to purchase up to 879 shares of the Company's common stock at an exercise price of $12.50 per pre-funded warrant. The pre-funded warrants mirror the terms of the pre-funded warrants issued to Corvus and were exercisable at any time on or after shareholder approval. On March 19, 2026, following receipt of stockholder approval, all 879 of the pre-funded warrants were exercised through a cashless exercise into 879 shares of the Company's common stock.

In connection with the second investment in Sarborg, the Company agreed to issue to the shareholders of Sarborg, pre-funded warrants to purchase up to 24,263 shares of the Company's Common Stock. On August 28, 2026, following the receipt of stockholder approval, all 24,263 of the pre-funded warrants were exercised on a cashless exercise, into 24,258 shares of the Company's common stock.

See Note 4 for further discussion of the investments in Sarborg.

Warrants - J.J. Astor Note

On June 11, 2026, in connection with the J.J. Astor Note, the Company issued J.J. Astor & Co., common stock purchase warrants to purchase 182 shares of the Company's Common Stock at an exercise price of $3,600.00 per share.

Further, on August 3, 2026, the Company and J.J. Astor & Co. entered into a third amendment to the J.J. Astor Note, in which the Company issued J.J. Astor additional warrants to purchase up to 75 shares of the Company's common stock at a purchase price of $3,600.00, in the same form of warrant issued to on June 11, 2026.

On August 28, 2026, at the Company's annual meeting of stockholders, stockholders approved the issuance of the 257 warrant shares upon exercise.

29

On August 31, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. In connection with the issuance of the note, the Company issued to J.J. Astor & Co. common stock purchase warrants to purchase 474 warrant shares at an exercise price of $845.00 per share. The Warrants are exercisable immediately upon the receipt of stockholder approval in accordance with the rules and regulations of Nasdaq and will expire five years from the date thereof.

On September 14, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. In connection with the issuance of the note, the Company issued to J.J. Astor & Co. common stock purchase warrants to purchase 6,937 shares of the Company's common stock at an exercise price of $125.00 per share. The Warrants are exercisable upon the receipt of stockholder approval in accordance with the rules and regulations of Nasdaq and will expire five years from the date thereof.

See Note 7 for further discussion of the J.J. Astor Notes

17. Segments

The Company has one operating segment focused on the research and development of clinical assets. The accounting policies of the single operating segment are identical to those described in Note 1. The Chief Operating Decision Maker ("CODM"), which the Company has identified as James Bligh, Chief Executive Officer and Chief Financial Officer, manages the Company's operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the unaudited condensed consolidated statements of operations and comprehensive loss. Depreciation expense, amortization expense, stock-based compensation expense, gain or loss from equity method investments and non-cash lease expense are significant noncash items included in consolidated net loss reviewed by the CODM and are reported on the unaudited condensed consolidated statements of cash flows. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets. Expenditures for additions to long-lived assets, which include purchases equipment and clinical assets, are included in total consolidated assets reviewed by the CODM and are reported on the unaudited condensed consolidated statements of cash flows.

The CODM uses consolidated net loss and budget-to-actual variances to assess the operating segment's performance and determine whether the Company is progressing towards its goals.

The following table presents specific financial data for the Company's reportable segment (in thousands):

Three months ended September 30, Nine months ended September 30,
(Dollar amounts in thousands) 2026 2025 2026 2025
Operating expenses:
Research & development expenses-clinical asset development $ 356 $ 209 $ 803 $ 620
Research & development expense - related parties 207 1,023 840 3,388
Research & development expense - related parties - digital assets - 300 - 300
General and administrative expenses - legal & professional fees 426 1,809 1,439 3,441
General and administrative expenses - accounting & audit fees 946 417 2,294 1,339
General and administrative expenses - salaries, payroll and stock based compensation 1,072 2,016 2,085 3,460
General and administrative expenses - digital assets - 231 - 299
General and administrative expenses - other 890 1,028 3,094 2,754
Total operating costs and expenses 3,897 7,033 10,555 15,601
Operating loss (3,897 ) (7,033 ) (10,555 ) (15,601 )
Other income (expenses):
Other income (expense) (257 ) (44 ) (2,083 ) (2,036 )
Loss on investment (298 ) - (452 ) -
Interest income - 7 - 19
Interest expense, net (131 ) (48 ) (197 ) (281 )
Total other (expense) income, net (686 ) (85 ) (2,732 ) (2,298 )
Net loss $ (4,583 ) $ (7,118 ) $ (13,287 ) $ (17,899 )

Other segment items consist of the items within Note 14 to the unaudited condensed consolidated financial statements.

30

18. Subsequent Events

J.J. Astor Fourth Convertible Note

On October 6, 2026, the Company issued a senior secured convertible promissory note to J.J. Astor & Co., in the principal amount of $6.8 million with aggregate proceeds of $5.0 million, to be funded in two tranches. This J.J. Astor Note has a maturity date of March 24, 2027, with repayment terms of twenty-four equal weekly installment payments of $169,000 to commence on October 14, 2026.

Additionally, the Company issued to J.J. Astor & Co., common stock purchase warrants, to purchase 11,250 shares of the Company's Common Stock at an exercise price of $18.35 per share. The warrants are exercisable subject to shareholder approval in accordance with the rules and regulations of Nasdaq.

At any time prior to the full payment of the convertible promissory note, J.J. Astor & Co., at its sole discretion, can elect to have all or any portion of the then-outstanding balance converted into shares of the Company's common stock, at a conversion price equal to the greater of 70% of the lowest closing price of the Company's common stock over the twenty consecutive trading days immediately preceding the date of conversion or the applicable floor price of $3.67. On December 11, 2026 and every six months until the note is paid off, the floor price is adjusted to equal to 20% of the lowest closing price of the Company's common stock during the 20 consecutive trading days immediately preceding the floor price reset date.

Manoira Agreement

On October 22, 2026 the Company and Manoira entered into an Evaluation Agreement whereby Manoira will analyze certain assets of CDT consisting of, among other things, clinical stage compounds AZD1656 and AZD5904 to determine whether they improve Manoira's animal healthcare business. Pursuant to the Agreement, the Company issued 67,380 shares of common stock, at a price of $2.894, which settled the total payment in the amount of $195,000 due to Manoira.

Shares Issued for Consulting Services

On October 22, 2026, the Company issued 19,868 shares of common stock to a service provider as consideration for certain consulting services.

Sarborg Investment

On October 22, 2026, and October 23, 2026 the Company issued, in the aggregate, 21,888 shares of Common Stock to Sarborg Limited as consideration pursuant to the securities purchase agreement with Sarborg, dated August 31, 2026.

Severance Shares

On October 23, 2026, the Company issued 24,980 shares of the Company's common Stock (the "Severance Shares") to Dr. Regan in lieu of $65,000 severance compensation in connection with his resignation as Chief Executive Officer of the Company.

Sales Agreement with A.G.P.

During October and November 2026, the Company sold 1,826,263 shares of the Company's Common Stock through the Sales Agreement with A.G.P.

31

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the related notes included under Part I, Item 1 of this Quarterly Report on Form 10-Q (this "Quarterly Report") as well as the Company's audited financial statements and notes thereto included in its Annual Report on Form 10-K for the year ended December 31, 2025 that was filed with the SEC on April 15, 2026. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. The following discussion contains forward-looking statements based upon current expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under the section titled "Risk Factors" or in other parts of this Quarterly Report. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. All dollar amounts are expressed in thousands of United States dollars ("$"), unless otherwise indicated.

Overview

On September 22, 2023, a merger transaction (the "Business Combination") between Conduit Pharmaceuticals Limited ("Old Conduit"), Murphy Canyon Acquisition Corp ("MURF") and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF ("Merger Sub"), was completed pursuant to the Agreement and Plan of Merger, dated November 8, 2022, as amended, (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. Effective August 5, 2025, the Company changed its name from Conduit Pharmaceuticals Inc. to CDT Equity Inc. Our change to CDT Equity Inc. reflects the evolution of our strategy as a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships.

CDT Equity is a data-driven pharmaceutical development company, focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.

CDT Equity's strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, the Company improves drug properties and extends patent life by up to 20 years. In partnership with Sarborg Limited ("Sarborg"), the Company also applies AI-powered signature analysis to rapidly identify new therapeutic applications and combinations for existing compounds.

Our pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. Ongoing in vitro and in vivo studies, guided by AI insights, are designed to support licensing and commercialization partnerships. The Company will seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials, by entering into agreements with third-parties to pursue further development, FDA approval, commercialization and marketing of the Company's assets.

On December 12, 2024, Sarborg and the Company entered into an agreement (the "Sarborg Agreement") designed to address longstanding challenges in the pharmaceutical sector, in particular by reducing human error in critical decision-making processes in both clinical development and asset identification. By integrating Sarborg's signature intelligence technology, the Company aims to enhance efficiency, lower costs, and accelerate timelines by minimizing human intervention, ultimately optimizing the drug development cycle and giving the Company a competitive advantage in the sector. Through this relationship, the Company will gain access to cutting-edge predictive models and dashboards, enabling the Company to evaluate drug candidates, streamline clinical trials, and optimize asset management with real-time data. These tools will drive faster, more accurate decisions, improving efficiency and reducing costs. By leveraging these insights, the Company can differentiate itself in a competitive sector and gain unique data-driven insights that position the Company for success across both its current and future asset portfolio. Our collaboration with Sarborg enables us to apply proprietary algorithms utilizing AI-powered disease mapping to identify novel re-purposing opportunities across a database of more than 3,000 disease signatures. Sarborg's insights have directly informed two new combination patent filings, strengthening our intellectual property portfolio. In addition, the Company has initiated pre-clinical in-vitro models to explore new indications, guided by AI-insights without human intervention. We will seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials, entering into agreements with third parties to pursue further development, FDA approval, commercialization, and marketing of our assets. We continue to evaluate novel artificial intelligence and cybernetics approaches to drug re-purposing, intellectual property, and asset selection to give the Company a competitive advantage. Sarborg is considered to be a related party of CDT, as Dr. Andrew Regan, a significant stockholder and the Company's former Chief Executive Officer, also sits on the board of directors of Sarborg and is a shareholder of Sarborg through his ownership of Corvus, Chele Chiavacci Farley, a director of CDT is also a shareholder of Sarborg and Ulrik Olsen, a director of CDT is also a shareholder of Sarborg.

32

During 2026, the Company and Sarborg furthered our partnership through strategic investments by the Company in Sarborg. See Note 4, Note 13 and Note 16 for further detail.

A further partnership with Manoira enables CDT Equity to expand the scope of its drug portfolio into the animal health market in a cost-efficient manner. This collaboration allows us to accelerate the understanding of the mechanism of action, safety, and potential efficacy of its portfolio across multiple species, while retaining 100% ownership of all data and intellectual property generated relating to human applications. This is expected to enhance the core human therapeutic pipeline but also opens potential new revenue streams in the high-growth veterinary market.

Repositioning the Company enables us to explore multiple opportunities in healthcare, biotech and broader technology innovation. Operating with a lean disease-agnostic model, the Company prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies. Led by highly experienced executive James Bligh, CEO and CFO; our management team includes active senior executives who also have an extensive understanding of the pharmaceutical market, supporting our strategy of developing clinical assets in a cost-efficient manner focused on therapeutic efficacy.

Furthermore, CDT Equity is well positioned to pursue, and intends to pursue, additional relationships and/or partnerships with third parties to license assets which are currently deprioritized. We plan to focus our efforts on developing clinical assets to address disorders that impact large populations where there is no present treatment or the existing treatments carry significant unwanted side effects.

Reverse Stock Split

The Company effected seven reverse stock splits of its common stock pursuant to amendments to the Company's Second Amended and Restated Certificate of Incorporation that were previously approved by the Company's stockholders and authorized by the Board of Directors. The reverse stock splits were implemented as follows: a 1-for-100 reverse stock split effective January 24, 2025, a 1-for-15 reverse stock split effective May 19, 2025, a 1-for-8 reverse stock split effective October 10, 2025, a 1-for-25 reverse stock split effective March 26, 2026, a 1-for-10 reverse stock split effective July 20, 2026, a 1-for-25 reverse stock split effective September 28, 2026, and a 1-for-20 reverse stock split effective November 5, 2026.

No fractional shares were issued in connection with the reverse stock splits. Stockholders who otherwise would have been entitled to receive fractional shares received cash in lieu of fractional shares based on the applicable post-split trading price of the Company's common stock. All references to numbers of shares of common stock and per-share information in this Interim Report on Form 10-Q have been adjusted retroactively, as appropriate, to reflect the reverse stock split.

Reverse stock splits were applied sequentially at their respective effective dates (resulting in a cumulative effect equivalent to an approximate 1-for-1,500,000,000 reverse stock split).

The reverse stock splits automatically combined the Company's issued and outstanding shares of common stock at the applicable ratios without affecting the number of authorized shares of common stock or the par value of $0.0001 per share. No fractional shares were issued in connection with the reverse stock splits. Stockholders who otherwise would have been entitled to receive fractional shares received cash in lieu of fractional shares based on the applicable post-split trading price of the Company's common stock.

33

As a result of the aggregate of the reverse stock splits, every 1,500,000,000 shares of our common stock issued or outstanding were automatically reclassified into and became one new share of common stock. The number of our issued and outstanding shares of common stock, when accounting for the reverse stock splits, was 73,866 and 18 shares as of September 30, 2026 and December 31, 2025, respectively.

In accordance with ASC 260, Earnings Per Share, all historical share and per-share amounts presented in the accompanying consolidated financial statements and related notes have been retroactively adjusted to reflect the effect of the reverse stock splits for all periods presented. Accordingly, all references to common stock share amounts and per-share information in this Interim Report on Form 10-Q have been retroactively adjusted, as applicable, to reflect the reverse stock splits.

Key Components of Results of Operations

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for the research and development of our candidates and programs. We expense research and development costs and intangible assets acquired that have no alternative future use as incurred. These expenses include:

● personnel-related expenses, including salaries, bonuses, benefits, and stock-based compensation for employees engaged in research and development functions;
● expenses incurred in connection with the clinical development and regulatory approval of our clinical assets, including under agreements with third parties, such as consultants, contractors, and CROs;
● license fees with no alternative use; and
● other research and development expenses.

We expense research and development costs with no alternative future use as incurred. Advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.

We incurred approximately $0.6 million and $1.6 million on research and development activities during the three and nine months ended September 30, 2026, respectively. We incurred approximately $1.5 million and $4.3 million on research and development activities during the three and nine months ended September 30, 2025, respectively. Our research and development activities have been focused on developing co-crystals of AZD1656 to increase patent life as well as purchasing technology to help us determine the feasibility that AZD1656, and potentially other de-prioritized assets, may reach commercialization. Some of this work was completed by third-party CROs but all intellectual property is retained by us. We currently have one pending international patent application and two pending national patent applications. The successful completion of clinical trials increases the value of clinical assets and may lead to the commercialization and/or licensing of such assets to other pharmaceutical companies. There is no assurance that any clinical trials on the assets owned or licensed by us will be successful.

Following our equity method investment in Sarborg, we note that revenue generated by Sarborg is not consolidated and the loss upon our equity method investment in Sarborg is discussed below.

34

General and Administrative Expenses

General and administrative expenses consist of salaries and other related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and other operating costs.

We anticipate that our general and administrative expenses will increase substantially for the foreseeable future as we increase our administrative headcount to operate as a public company and as we advance clinical assets through clinical development. We also will incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC and the Nasdaq listing rules, additional insurance expenses, investor relations activities and other administrative and professional services. In addition, if regulatory approval is obtained for clinical assets, we expect to incur expenses associated with building a sales and marketing team.

Other Income (Expenses)

Other income (expenses), net

Other income (expenses), net consists of change in the fair value of options, change in fair value of convertible notes and expense incurred upon the issuance of warrants during the nine months ended September 30, 2026.

Loss on equity method investment

Loss on equity method investment consists of our pro rata portion of losses incurred through our 22.74% equity method investment in Sarborg. See Note 4, Note 13 and Note 16 for further discussion of our relationship with Sarborg.

Interest expense, net

Interest expense, net consists primarily of interest expense on convertible notes, promissory notes and interest expense on deferred commissions payable to an advisor for fees related to the merger, as well as a small amount of interest income on cash and cash equivalents held by the Company.

Results of Operations

The following table sets forth our results of operations for the periods indicated:

Three Months Ended
September 30,
Nine Months Ended
September 30,
(Dollar amounts in thousands) 2026 2025 2026 2025
Operating expenses:
Research and development expenses $ 563 $ 1,532 $ 1,643 $ 4,308
General and administrative expenses 3,334 5,501 8,912 11,293
Total operating costs and expenses 3,897 7,033 10,555 15,601
Operating loss (3,897 ) (7,033 ) (10,555 ) (15,601 )
Other expenses:
Other expense, net (257 ) (44 ) (2,083 ) (2,036 )
Loss on equity method investment (298 ) - (452 ) -
Interest income - 7 - 19
Interest expense, net (131 ) (48 ) (197 ) (281 )
Total other expense, net (686 ) (85 ) (2,732 ) (2,298 )
Net loss $ (4,583 ) $ (7,118 ) $ (13,287 ) $ (17,899 )
35

Comparison of the Three Months Ended September 30, 2026 and 2025

Research and Development Expenses

Three Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Research and development expenses $ 563 $ 1,532 $ (969 ) (63 )%

Research and development expenses decreased by approximately $1.0 million, or 63%, to $0.6 million for the three months ended September 30, 2026, as compared to $1.5 million for the three months ended September 30, 2025. The decrease was primarily attributable to a $1.0 million decrease in expense related to our transactions with Sarborg and a $0.1 million decrease related to the Thesprogen agreement during the three months ended September 30, 2026.

General and Administrative Expenses

Three Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
General and administrative expenses $ 3,334 $ 5,501 $ (2,167 ) (39 )%

General and administrative expenses decreased by $2.2 million, or 39%, to $3.3 million for the three months ended September 30, 2026, compared to $5.5 million for the three months ended September 30, 2025. The decrease was driven by a $0.9 million decrease in salaries and stock-based compensation, a $0.9 million decrease in legal, accounting and professional fees, a $0.2 million decrease in travel expenses and a $0.1 million decrease in insurance expense.

Other Expense, Net

Three Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Other expense, net $ (257 ) $ (44 ) $ (213 ) 484 %

Other expense, net increased by $0.2 million or 484%, to $0.3 million for the three months ended September 30, 2026, compared to $44,000 for the three months ended September 30, 2025. The increase was driven by an increase of $1.1 million of expense related to loss on debt extinguishment, partially offset by a $0.6 million gain on a decrease of the investment payable balance to Sarborg, and a $0.1 million net gain from changes in fair value of convertible notes payable and warrant liabilities, and a $0.1 million increase in the research and development tax receivable recorded during the three months ended September 30, 2026.

For further details refer to Note 14 in the unaudited condensed consolidated financial statements included elsewhere in this document.

Loss on Investment

Three Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Loss on investment $ (298 ) $ - $ (298 ) N/M

Loss on equity method investments was $0.3 million for the three months ended September 30, 2026. The loss was driven by a loss on the change in the carrying value of our investment in Sarborg with no comparable activity during the three months ended September 30, 2025.

36

Interest Expense, Net

Three Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Interest expense, net $ (131 ) $ (48 ) $ (83 ) 173 %

Interest expense, net increased by approximately $83,000, or 173%, to $0.1 million for the three months ended September 30, 2026, as compared to $48,000 for the three months ended September 30, 2025. The increase was driven by accrued interest expense recorded during the three months ended September 30, 2026 related to the outstanding J.J. Astor convertible note.

Comparison of the Nine Months Ended September 30, 2026 and 2025

Research and Development Expenses

Nine Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Research and development expenses $ 1,643 $ 4,308 $ (2,665 ) (62 )%

Research and development expenses decreased by $2.7 million, or 62%, to $1.6 million for the nine months ended September 30, 2026, as compared to $4.3 million for the nine months ended September 30, 2025. The decrease was primarily attributable to a $2.8 million decrease in expense related to research and development activity with Sarborg.

General and Administrative Expenses

Nine Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
General and administrative expenses $ 8,912 $ 11,293 $ (2,381 ) (21 )%

General and administrative expenses decreased by $2.4 million, or 21%, to $8.9 million for the nine months ended September 30, 2026, compared to $11.3 million for the nine months ended September 30, 2025. The decrease was primarily driven by a $1.0 million decrease in legal, accounting and professional fees, and a $1.4 million decrease in salaries and stock-based compensation and a $0.2 million decrease in insurance expense, partially offset by a $0.2 million increase in other general and administrative expenses.

Other Expense, Net

Nine Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Other expense, net $ (2,083 ) $ (2,036 ) $ 47 2 %

Other expense, net increased by $47,000 or 2%, to $2.1 million for the nine months ended September 30, 2026, compared to $2.0 million for the nine months ended September 30, 2025. The increase was driven by an increase in net losses on debt extinguishment of $1.9 million, and a decrease of $0.4 million in gains upon a waiver of accrued interest, partially offset by a $1.5 million decrease in expenses related to changes in fair value of convertible notes payable and warrant liabilities and a $0.7 million gain on the decrease investment payable balance to Sarborg.

For further details refer to Note 14 in the unaudited condensed consolidated financial statements included elsewhere in this document.

37

Loss on Investment

Nine Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Loss on investment $ (452 ) $ - $ (452 ) N/M

Loss on equity method investments was $0.5 million for the nine months ended September 30, 2026. The loss was driven by a loss on the change in the carrying value of our investment in Sarborg with no comparable activity during the nine months ended September 30, 2025

Interest Expense, Net

Nine Months ended
September 30,
Change
(Dollar amounts in thousands) 2026 2025 Amount %
Interest expense, net $ (197 ) $ (281 ) $ 84 (30 )%

Interest expense, net decreased by $0.1 million, or 30%, to $0.2 million for the nine months ended September 30, 2026, as compared to $0.3 million for the nine months ended September 30, 2025. The decrease was primarily driven by a decrease of $65,000 related to a convertible promissory note negotiation fee incurred during the nine months ended September 30, 2025 with no comparable activity during the nine months ended September 30, 2026. The remaining decrease is attributable to a lower balance of convertible notes outstanding during the nine month ending September 30, 2026 as compared to the nine months ended September 30, 2025, resulting in lower interest expense.

Liquidity and Capital Resources

Management assesses liquidity in terms of our ability to generate cash to fund operating, investing and financing activities. Since our inception, and in line with our growth strategy, we have prepared our financial statements assuming we will continue as a going concern. Since our inception, we have incurred net losses and experienced negative cash flows from operations. To date, our primary sources of capital have been through convertible debt, private placements of equity securities and the Sales Agreement with A.G.P. During the nine months ended September 30, 2026 and 2025, we incurred net losses of $13.3 million and $17.9 million, respectively.

Sources and Uses of Liquidity

Our primary use of cash is to fund our operations as we continue to grow our business. We will require a significant amount of cash for expenditures as we invest in ongoing research and development and business operations. Until such time we can generate significant revenue from the successful approval and commercialization of a product candidate, we expect to finance our cash needs for ongoing research and development and business operations through public or private equity or debt financings or other capital sources, including strategic partnerships. However, we may be unable to raise additional funds or enter into such other arrangements, when needed, on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be, or could be, diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. We have also considered exploring strategic alternative paths to fund raising through a shift in our fundamental operations as a pharmaceutical development company to a digital asset treasury management company. If we are unable to raise additional funds through equity or debt financing when needed, we may be required to delay, limit, or substantially reduce research and development efforts all of which could have a material adverse effect on the Company and its financial results.

While the Company believes in the viability of its ability to raise additional funds, there can be no assurances to that effect. We have based our estimates on assumptions of operating costs that may prove to be wrong. As a result, we could deplete our capital resources sooner than we currently expect. If, for any reason, our expenses differ materially from our assumptions or we utilize our cash more quickly than anticipated, or if we are unable to obtain funding on a timely basis we may be required to revise our business plan and strategy, which may result in significantly curtailing, delaying or discontinuing one or more of our research or development programs or the commercialization of any product candidates or may result in our being unable to expand our operations or otherwise capitalize on our business opportunities. As a result, our business, financial condition, and results of operations could be materially affected.

38

Management has concluded that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months from the date of the filing of this Quarterly Report. This is based on our analysis under applicable accounting principles. These unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include adjustments to reflect the possible effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Cash Requirements

Our material cash requirements include the following contractual and other obligations.

Investment in Sarborg

On February 19, 2026, the Company entered into a Securities Purchase Agreement with all of the stockholders of Sarborg. The investors of Sarborg agreed to sell to the Company, and the Company agreed to acquire from the investors, an aggregate of 1,020 shares of Sarborg, representing approximately 20% of the outstanding common stock of Sarborg.

As consideration for the purchase, the Company agreed to issue to the investors 4 shares of the Company's Common Stock, and warrants that were exercised to purchase 879 shares of Common Stock. In addition, the Company has agreed to pay Sarborg cash consideration of $8.0 million, with the cash portion of the consideration deferred until such time as the Company raises no less than $20.0 million through the use of an at-the-market facility program.

On August 31, 2026 Company entered into an amendment to the Securities Purchase Agreement. Pursuant to the amendment: $1.8 million of the $8.0 million cash consideration may be satisfied through the issuance of shares of the Company's Common Stock to Sarborg. In addition, the remaining cash consideration will be paid from proceeds of the Company's at-the-market program, with the Company agreeing to make minimum payments of $0.2 million per month and with any remaining outstanding balance due no later than May 31, 2027. On August 31, 2026, the Company issued 1,300 shares of Common Stock to Sarborg, to satisfy $1.1 million payable in shares of the Company's Common Stock.

As of September 30, 2026, $5.4 million of the cash portion and $0.7 million of the Common Stock portion of consideration due for the investment in Sarborg was still outstanding. We expect to raise the funds through an at-the-market facility program and repay the outstanding cash balance no later than May 31, 2027.

Refer to Note 4 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

A.G.P Convertible Note

On November 25, 2024, the Company issued to A.G.P. a convertible promissory note (the "A.G.P. Convertible Note") in the principal amount of $5.7 million to evidence A.G.P.'s currently owed deferred commission payable. Unless earlier converted as specified in the A.G.P. Convertible Note, the principal amount plus all accrued but unpaid interest is due on November 25, 2025 (the "Maturity Date"). The A.G.P. Convertible Note accrues interest at 5.5% per annum.

At any time prior to the full payment of the A.G.P. Convertible Note, provided that A.G.P. has given at least three business days written notice to the Company, A.G.P., in its sole discretion, may elect to have all or any portion of the outstanding principal amount and all interest accrued converted into shares of the Company's Common Stock, at the lower of the Reverse Split price and the market price per share at the time of the conversion date, but in no event less than $1.00, subject to adjustment as provided therein and to take into account any future share splits or reverse splits. However, the conversion of the A.G.P. Convertible Note may not occur prior to the Company having sufficiently authorized shares of Common Stock to permit the entire conversion of the convertible promissory note. Refer to Note 7 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

39

During the nine months ended September 30, 2026, the holder of the A.G.P. Convertible Note converted the remaining $2.5 million of principal and interest into 255 shares of the Company's Common Stock.

First J.J. Astor Convertible Note

On June 11, 2026, the Company issued a senior secured convertible promissory note (the "Note") to J.J. Astor & Co. (the "Lender"), in the principal amount of $2.0 million. The Company will receive net proceeds of $1.5 million, before deduction of closing fees and was funded in two tranches.

The Note is payable to the Lender over twenty-four equal weekly installments of $82,000 commencing on July 10, 2026, which may be paid in cash or, at the option of the Company, once an applicable resale registration statement is declared effective by the Securities and Exchange Commission covering the resale of any shares of the Company's common stock that may be received on such conversion.

Additionally, the Company issued the Lender, common stock purchase warrants to purchase 182 shares of the Company's Common Stock at an exercise price of $3,600.00 per share. The Warrants became exercisable beginning on the effective date of stockholder approval of the issuance of the Warrant Shares (such date, the "Stockholder Approval Date") and will expire five years after the Stockholder Approval Date.

Second and Third Amendments to J.J. Astor First Convertible Note

On July 31, 2026, the Company entered into a second amendment to the J.J. Astor Note discussed in Note 7. The Company failed to make three scheduled weekly installment payments of $82,000 due July 17, July 24, and July 31, 2026, totaling $246,000, and had not filed the required resale registration statement by its deadline.

Under this amendment, the lender agreed to treat these matters as an accommodation, rather than an event of default, but expressly reserved all rights if any future payment default occurs.

In connection with the accommodation, the total principal balance was increased by a $378,000 restructuring premium, to a total amended principal balance due to J.J. Astor of approximately $2.3 million and increased the default interest rate from 19% to 24% per annum upon any future event of default. The amendment reschedules repayment into 23 weekly installments of approximately $104,000, that commenced on August 19, 2026 through a new maturity date of January 20, 2027. The amendment also updated the registration statement filing requirement deadline to August 31, 2026, with any further delay constituting an immediate event of default.

On August 3, 2026, the Company and J.J. Astor & Co. entered into Third Amendment. Pursuant to the Third Amendment, J.J. Astor advanced $0.2 million to the Company, subject to fees, and increased the outstanding principal balance of the Amended Note to approximately $2.5 million.

Second J.J. Astor Convertible Note

On August 31, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. (the "August 2026 Note"), in the principal amount of $541,620. The Company received $401,000 before deducting closing fees, with net proceeds of $375,000 funded to the Company. On September 4, 2026, the August 2026 Note was repaid in full and is no longer outstanding.

Third J.J. Astor Convertible Note

On September 14, 2026, the Company issued an additional senior secured convertible promissory note to J.J. Astor & Co. (the "September 2026 Note"), in the principal amount of $2.1 million. The Note matures on March 1, 2027 and is payable in twenty-four weekly installments of $89,000 starting on September 21, 2026. The Note was issued pursuant to the first Loan Agreement, dated as of June 11, 2026, as amended and restated to date between the Company, and J.J. Astor & Co. The Company received $1.6 million before deducting closing fees, with net proceeds of $1.5 million funded to the Company.

40

J.J. Astor Fourth Convertible Note

On October 6, 2026, the Company issued a senior secured convertible promissory note to J.J. Astor & Co., in the principal amount of $6.8 million with aggregate proceeds of $5.0 million, to be funded in two tranches. This J.J. Astor Note has a maturity date of March 24, 2027, with repayment terms of twenty-four equal weekly installment payments of $169,000 to commence on October 14, 2026.

See Note 7 for further discussion of the J.J. Astor Note.

Working Capital

We currently anticipate that cash required for working capital for the next 12 months is approximately $28.4 million, which includes forecasted research and development costs of $0.1 million forecasted general and administrative costs of $5.9 million, current liabilities of $20.2 million and convertible promissory notes payable, if not converted prior to maturity of $2.2 million. We do not anticipate being able to fund required working capital for the next 12 months with cash and cash equivalents on hand and current borrowings. Management believes that we will be able to fund cash required for the next 12 months through borrowings and equity raises. We have historically been able to access funds through the issuance of debt, and more recently our at the market offering program through the Sales Agreement and believe we can continue to obtain funding through such debt financing agreements and Sales agreement as needed to meet cash requirements for the next 12 months.

Cash Flows

The following table sets forth our cash flows for the period indicated (in thousands):

Nine Months ended September 30,
2026 2025
Net cash provided (used in) by:
Operating activities $ (5,315 ) $ (10,919 )
Investing activities (150 ) (1,403 )
Financing activities 5,679 15,681
Effect of exchange rate changes on cash and cash equivalents - (75 )
Net (decrease) increase in cash and cash equivalents $ 214 $ 3,284

Cash Flows Used in Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2026, was $5.3 million, resulting primarily from a net loss of $13.3 million, adjusted for non-cash items including: a $1.2 million loss on the change in fair value of convertible notes payable, $1.4 million of amortization expense, $2.2 million loss on debt extinguishment, $0.9 million of amortization of directors and officers insurance, $1.0 million issuance of common stock for services, $0.3 million of non-cash interest expense , $0.6 million of stock-based compensation, $0.5 million loss on equity method investment, a $0.1 million of non-cash lease expense a $0.6 million gain on the waiver of consideration payable for an investment in related party, a $0.5 million gain on the change in fair value of derivative warrant liability and a $1.0 million cash inflow from operating assets and liabilities. The $1.0 million cash inflow from changes in operating assets and liabilities is primarily due to a $2.6 million cash inflow from accounts payable, a $0.2 million cash inflow from accrued expenses, partially offset by a $1.7 million cash outflow from prepaid expenses and other current assets and a $0.1 million cash outflow from operating lease liabilities.

Net cash used in operating activities for the nine months ended September 30, 2025, was $10.9 million, resulting primarily from a net loss of $17.9 million, adjusted for non-cash items including a $0.4 million gain on waiver of accrued interest, $0.3 million gain on debt extinguishment, $0.1 change in fair value of derivative warrant liability, a $3.0 million change in fair value of convertible notes, $3.0 million of amortization expense, $2.0 million of stock-based compensation, $0.3 million of non-cash interest expense, and a $0.6 million cash outflow from operating assets and liabilities. The $0.6 million cash outflow from operating assets and liabilities is primarily due to a $0.8 million cash outflow from accounts payable, a $0.1 million cash outflow from operating lease liabilities and a $0.2 million cash outflow from prepaid expenses and other current assets, partially offset by a $0.5 million cash inflow from accrued expenses and other current liabilities.

41

Cash Flows Used in Investing Activities

Cash used in investing activities for the nine months ended September 30, 2026 was $0.2 million. This was for a partial payment of consideration due in connection to the investment in Sarborg.

Net cash used in investing activities for the nine months ended September 30, 2025, was $1.4 million, resulting from $0.4 million in diagnostic asset purchases and $1.0 million in digital asset purchase as a part of our digital asset treasury strategy.

Cash Flows Provided by Financing Activities

Net cash provided by financing activities for the nine months ended September 30, 2026, was $5.7 million, resulting from proceeds received from the issuance of convertible notes payable of $3.9 million, and from proceeds from the issuance of common shares related to the ATM program of $5.6 million, partially offset by repayments of notes payable of $3.8 million.

Net cash provided by financing activities for the nine months ended September 30, 2025, was $15.7 million, resulting from proceeds from the issuance of common shares related to the ATM program of $18.0 million, partially offset by repayments of notes payable of $0.2 million, repayments of notes payable - related parties of $0.4 million, repayment of convertible notes payable - related parties of $0.9 million, repayment of convertible notes payable of $0.7 million, and treasury stock purchases of $0.1 million.

Contractual Obligations and Other Commitments

Laboratory Lease

We are the lessee under a laboratory space lease. The remaining annual rent payments are $0.1 million for the year ending December 31, 2026. The laboratory space lease has a remaining lease term of approximately one year.

Critical Accounting Estimates

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. These estimates, judgments and assumptions are evaluated on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe are reasonable at that time, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates. The accounting policies that reflect our more significant estimates, judgments and assumptions and which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

Fair Value of Convertible Notes

The Company has elected the fair value measurement option for convertible debt with embedded derivatives that would otherwise require bifurcation and has recorded the entire hybrid financial instrument at fair value under the guidance in ASC Topic 825, Financial Instruments. To value the convertible debt, the Company utilizes Binomial Lattice Pricing Models. The Binomial Lattice Pricing Models involve the construction of various intermediate lattices: stock price tree, conversion value tree, conversion probability tree, and discount rate tree. In doing so, we assume the holders act rationally to maximize return and minimize cost at each decision point. We computed the notes payoff at maturity and at intermediate decision nodes based upon the better of (i) conversion or (ii) repayment of principal and interest.

42

The significant inputs and assumptions used to estimate the fair value include: (i) the Company's stock price; (ii) the term of the convertible debt; (iii) the sum of the notes' principal and unpaid accrued interest; (iv) expected volatility; (v) risk-free interest rate; (vi) the corporate bond yield; (vii) the credit spread; (viii) probability of default; and (ix) the estimated recovery upon default. Any change to the unobservable inputs to estimate fair value could produce significantly higher or lower fair value measurements and result in a material change within the unaudited condensed consolidated financial statements.\

The convertible debt will subsequently be remeasured at fair value each reporting date until settled or converted.

Investments

Management evaluates investments in unconsolidated entities to determine whether the Company has the ability to exercise significant influence over the investee's operating and financial policies in accordance with ASC 323, Investments-Equity Method and Joint Ventures. This assessment requires significant judgment and consideration of both qualitative and quantitative factors, including, but not limited to, ownership interest, board representation, participation in policy-making processes, material intercompany transactions, commercial relationships, contractual rights, and the relative concentration of ownership among other shareholders. Investments in which the Company does not have the ability to exercise significant influence are accounted for in accordance with ASC 321, Investments - Equity Securities ("ASC 321").

The Company's current investment is accounted for under the equity method of accounting, under which the Company records its proportionate share of the investee's earnings and losses within earnings and evaluates the investment for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable. The determination of whether a decline in value is other-than-temporary requires significant judgment regarding the investee's financial condition, operating performance, business prospects, market conditions, and estimated recoverable value.

Changes in facts and circumstances, including changes in governance rights, ownership structure, commercial arrangements, financing activities, or the investee's operating performance, could result in changes to management's conclusions regarding significant influence or impairment and may materially impact the Company's unaudited condensed consolidated financial statements in future periods.

Contingencies

In the ordinary course of business, we are involved in various legal proceedings that are complex in nature and have outcomes that are difficult to predict. We describe our legal proceedings and other matters that are significant or that we believe could become significant in Note 15 to the unaudited condensed consolidated financial statements. We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred, and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause an increase or decrease in the amount of liability that has been accrued previously or modifications to contingency disclosures that are considered material.

Emerging Growth Company Status and Smaller Reporting Company Status

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act"). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that: (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

43

Upon closing of the Merger, the surviving company remained an emerging growth company, as defined by the JOBS Act until the earliest of (i) the last day of the combined entity's first fiscal year following the fifth anniversary of the completion of MURF's initial public offering, (ii) the last day of the fiscal year in which the combined entity has total annual gross revenue of at least $1.235 billion, (iii) the last day of the fiscal year in which the combined entity is deemed to be a large accelerated filer, which means the market value of the combined entity's Common Stock that is held by non-affiliates exceeds $700.0 million as of the prior December 31st or (iv) the date on which the combined entity has issued more than $1.0 billion in non-convertible debt securities during the prior three year period.

In addition, CDT Equity is a smaller reporting company as defined in the Securities Exchange Act of 1934 (as amended, the "Exchange Act"). The Company may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) CDT Equity's voting and non-voting Common Stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) CDT Equity's annual revenue is less than $100.0 million during the most recently completed fiscal year and its voting and non-voting Common Stock held by non-affiliates is less than $700.0 million measured on the last business day of its second fiscal quarter.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure regarding quantitative and qualitative market risk.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Under the supervision and with the participation of our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the fiscal quarter ended September 30, 2026, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that during the periods covered by this Quarterly Report, our disclosure controls and procedures were not effective, due to material weaknesses previously identified and included in the Company's most recent Form 10-K as not yet remediated as of the end of both such periods.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter. On August 31, 2026, Dr. Regan resigned from the Company's Board of Directors and as Chief Executive Officer. Effective immediately, James Bligh was appointed Chief Executive Officer. Mr. Bligh will also continue to serve as Chief Financial Officer until a replacement is named.

44

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is subject to certain claims and contingent liabilities that arise in the normal course of business. While we do not expect that the ultimate resolution of any of these pending actions will have a material effect on our consolidated results of operations, financial position or cash flows, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, does not become material in the future. For information on the Company's current legal proceedings see Note 15 - Commitments and Contingencies - Legal Proceedings in our unaudited condensed consolidated financial statements.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide disclosure regarding material changes to our previously disclosed risk factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

No unregistered sales of equity securities occurred during the quarter ended September 30, 2026 that were not previously reported.

The Company did not repurchase any of its Common Stock during the nine months ended September 30, 2026.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

During the nine months ended September 30, 2026, none of our executive officers or directors (as defined in Section 16 of the Securities Exchange Act of 1934, as amended), adopted, terminated, or modified a "Rule 10-b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" (as defined in Item 408(c) of Regulation S-K).

45

Item 6. Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Exhibit
3.1 Certificate of Amendment filed with the Delaware Secretary of State on May 15, 2025 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on May 16, 2025).
3.2 Certificate of Amendment filed with the Delaware Secretary of State on August 5, 2025 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on August 8, 2025).
3.3 Certificate of Amendment filed with the Delaware Secretary of State on October 8, 2025 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on October 9, 2025).
3.4 Second Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on August 8, 2025).
3.5 Certificate of Amendment filed with the Delaware Secretary of State on March 24, 2026 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on March 25, 2026).
3.6 Certificate of Amendment filed with the Delaware Secretary of State on July 15, 2026 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on July 16, 2026).
3.7 Certificate of Amendment filed with the Delaware Secretary of State on September 24, 2026 (incorporated by reference Exhibit 3.1 to the Company's Current Report on Form 8-K filed on September 25, 2026).
3.8 Certificate of Amendment filed with the Delaware Secretary of State on November 2, 2026 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on November 4, 2026).
10.1 Form of Securities Purchase Agreement, dated July 30, 2026 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on July 31, 2026).
10.2 Form of Pre-Funded Warrant issued July 30, 2026 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on July 31, 2026).
10.3 Second Amendment between the Company and J.J. Astor & Co., dated July 31, 2026 (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 6, 2026).
10.4 Third Amendment between the Company and J.J. Astor & Co., dated August 3, 2026 (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 6, 2026).
10.5+ Employment Agreement, dated August 31, 2026, between James Bligh and the Company (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on September 1, 2026).
10.6 Form of Common Stock Purchase Warrant issued August 31, 2026 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on September 4, 2026).
10.7 Amendment No. 1, dated August 31, 2026, to the Securities Purchase Agreement, dated February 19, 2026, between CDT Equity Inc. and Sarborg Limited (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on September 4, 2026).
10.8 Senior Secured Convertible Note, dated August 31, 2026, between CDT Equity Inc. and J.J. Astor & Co. (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on September 4, 2026).
10.9+ Non-Employee Director Compensation Program (incorporated by reference to Exhibit 10.49 to the Company's Registration Statement on Form S-1 (File No. 333-298808) filed on September 8, 2026).
10.10 Form of Common Stock Purchase Warrant issued September 14, 2026 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on September 18, 2026).
10.11 Senior Secured Convertible Note, dated September 14, 2026, between CDT Equity Inc. and J.J. Astor & Co. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on September 18, 2026).
10.12 Form of Common Stock Purchase Warrant issued October 6, 2026 (incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed on October 13, 2026).
10.13 Senior Secured Convertible Note, dated October 6, 2026, between CDT Equity Inc. and J.J. Astor & Co. (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 13, 2026).
10.14 Evaluation Agreement, dated October 22, 2026, between CDT Equity Inc. and Manoira Corporation (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on October 27, 2026).
31.1* Certification of Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* Certification of Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1§ Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2§ Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* Inline XBRL Instance Document.
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.SCH* Inline XBRL Taxonomy Extension Schema Document.
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
* Filed herewith.
§ In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management's Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto is deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed "filed" for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
46

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CDT EQUITY INC
November 16, 2026 By: /s/ James Bligh
Name: James Bligh
Title: Chief Executive Officer
(Principal Executive Officer)
November 16, 2026 By: /s/ James Bligh
Name: James Bligh
Title: Chief Financial Officer
(Principal Financial and Accounting Officer)
47

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, James Bligh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of CDT Equity Inc. (the Registrant);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to me by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
November 16, 2026 /s/ James Bligh
James Bligh
Chief Executive Officer (Principal Executive Officer)

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, James Bligh, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of CDT Equity Inc. (the Registrant);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and we have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and
5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
November 16, 2026 /s/ James Bligh
James Bligh
Chief Financial Officer (Principal Financial Officer)

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, I, James Bligh, Chief Executive Officer of CDT Equity Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

(1) Such Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in such Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, fairly presents, in all material respects, the financial condition and results of operations of CDT Equity Inc.
November 16, 2026 /s/ James Bligh
James Bligh
Chief Executive Officer (Principal Executive Officer)

A signed original of the certification required by Section 906 has been provided to CDT Equity Inc. and will be retained by CDT Equity Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, I, James Bligh, Chief Financial Officer of CDT Equity Inc., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

(1) Such Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in such Quarterly Report on Form 10-Q of CDT Equity Inc. for the period ended September 30, 2026, fairly presents, in all material respects, the financial condition and results of operations of CDT Equity Inc.
November 16, 2026 /s/ James Bligh
James Bligh
Chief Financial Officer (Principal Financial Officer)

A signed original of the certification required by Section 906 has been provided to CDT Equity Inc. and will be retained by CDT Equity Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

CDT Equity Inc. published this content on November 17, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 17, 2026 at 14:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]